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ABSTRACT 
PRESCRIPTION OPIOIDS AND ADOLESCENTS: FACTORS ASSOCIATED WITH 
NONMEDICAL USE AND PRESCRIBING PRACTICES 
Sydney A. Axson, MPH, RN 
Jennifer A. Pinto-Martin, PhD, MPH 
Since peaking in the 2000s, increased attention has focused on the use of prescription 
opioids. While much is known about the use of these medications in adults, much less is 
understood about their use in the adolescent population. This dissertation first synthesized 
the literature to identify and discuss factors associated with the non-medical use of 
prescription drugs. These factors are important to consider in weighing the benefits and 
risks of prescription medications, including opioids, for adolescent patients. Next, a 
cross-sectional analysis of adolescents discharged from one hospital system with a pain 
medication between January 2015 and January 2017 was conducted to identify factors 
associated with receiving and opioid prescription after an acute care visit of 48 hours or 
less. This analysis identified older age, higher pain scores, and having surgery to be 
associated with increased odds of being discharged with an opioid prescription. Patients 
on Medicaid or who self-pay, as well as those discharged from an emergency department 
or urgent care center were significantly less likely to receive an opioid prescription. 
Prescriber licensure, race, and gender were not significantly associated with opioid 
prescribing. Next, using the electronic health record, a cross-sectional analysis of a 
random sample of over 9,000 patients discharged from one hospital system after a stay of 
5 days or less from January 2015 to December 2019 was conducted to understand 
prescribing over time. Four outcome groups were created to conduct a multivariable 
multinomial logistic regression 1) discharged with no medication, 2) discharged with a 
non-opioid only, 3) discharged with an opioid only, 4) discharged with both an opioid 
and a non-opioid. Controlling for patient and clinical characteristics that may contribute 
to the need for an opioid medication, we found that the odds of receiving an opioid only 
at time of discharged decreased over time, while receiving a non-opioid only at time of 
discharge increased over time. Collectively, this dissertation contributes to an 
understanding of prescribing opioids to adolescent patients. Findings from this work will 
be helpful for developing future nurse-led educational interventions aimed to promote 
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Chapter 1  
Introduction 
Adverse health outcomes related to the nation’s opioid consumption, including addiction, 
injury, and overdose deaths continue to rise in all 50 states.1-5 According to the Centers 
for Disease Control and Prevention (CDC), the current opioid epidemic is a top public 
health priority.3 Between 1999 and 2012, rates of prescribing opioids increased 
dramatically: the nation’s consumption of oxycodone increased 500%, hydrocodone 
doubled, and opioid overdose deaths quadrupled.2,6-8 At opioid prescribing peak in 2012, 
259 million prescriptions were written, creating a public supply of opioids large enough 
to provide a bottle for every adult in America.9  
While adults over 18 represent the majority of these statistics, prescribing for young 
people also increased and adolescents were similarly at risk of negative outcomes related 
to prescription opioids. In an overlapping timeframe (2000-2015), adolescents aged 15-19 
experienced a 91% increase in fatal poisonings, a finding the CDC finds consistent with 
the increase in concurrent drug-related deaths in the overall population during the same 
time.10,11 Importantly, adolescents can be exposed to opioid medications in the health care 
system or through a family or peer sharing medication.12 As a result, nearly 25% of high 
school seniors report lifetime exposure to prescription opioids, the majority reporting 
their first exposure as medical.12 Health care is not the only source of opioid exposure, 
but it is a prominent source with potentially long-lasting implications. 
The relationship between opioid exposure for medical use during adolescence and the 
development of a substance use disorder later in life has yet to be fully understood. 
However, evidence suggests that receiving an opioid prescription by 12th grade increases 
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the risk of future non-medical use (misuse) by 33% by the age of 23 compared to those 
not receiving an opioid prescription.13 Similar findings have been reported up to the age 
of 35.1 Initiation of non-medical use of prescription opioids during the adolescent years 
has also been associated with increased odds of opioid use disorders later in life.1,2,13-15 
Medical prescriptions are a top source of initial opioid exposure in adolescents, followed 
by peers sharing leftover prescriptions.16 This evidence highlights the critical need to 
better understand how and why prescriptions are introduced to the adolescent community 
and the associated risk factors for misuse. 
Health care providers are charged with effectively managing pain in the context of 
growing adverse outcomes related to opioids. This mission is further complicated when 
considering the impact these drugs have on adolescents throughout their lifespan. 
Responsible medical use of prescription opioids includes balancing the utility of the 
medications with their associated risks. Achieving this balance requires evidence 
informing best practice. While it is known that the great majority of substance use 
disorders have onset during adolescence, and that exposure to opioids, even for medical 
reasons, represents a significant risk, adolescents are rarely the focus of research and safe 
prescribing guidelines. It remains critically important to describe how these medications 
are used in current practice to both evaluate prescribing practices and further inform best 
practices and guidelines.  
This dissertation examines how adolescents are prescribed opioids through a health 
care system. This chapter is an overview of the relevant concepts related to this 
dissertation, beginning with the background of the current opioid climate, the 
significance of adolescence, and concluding with opioid medications. This chapter aims 
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to provide the foundation and operational definitions needed to approach the proposed 
dissertation. The following three chapters include the component manuscripts that 
comprise this dissertation. Chapter two is a systematic review of literature addressing risk 
factors associated with the misuse of prescription medications in adolescence. This 
review serves to inform this dissertation’s approach to understanding the misuse potential 
of prescription drugs, including opioids. This literature review is needed to understand 
the important context of how prescriptions drugs can be used once they enter an 
adolescent’s community and which factors may contribute to patterns of prescription 
drug misuse. Further, identifying risk factors associated with misuse of prescription drugs 
will be useful for promoting safe use. Chapters three and four are cross sectional studies 
examining opioid prescribing data from the electronic health record (EHR) of the 
Children’s Hospital of Philadelphia (CHOP). Analyses conducted in these chapters 
describe and characterize opioid prescribing at time of discharge from an acute care 
setting. The findings can inform prescribing practices and will be useful to clinicians and 
researchers developing targeted education and intervention efforts for adolescents, and 
their families, going home with an opioid prescription. The specific aims of this 
dissertation are to: 
1. Identify factors associated with adolescent non-medical use of prescription 
drugs. (Chapter 2) 
2. Characterize opioid prescribing in a sample of adolescents who received a 
pain medication prescription (opioid and non-opioid) upon discharge after a 
hospital admission of 2 days or less. (Chapter 3) 
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3. Evaluate trends in opioid prescribing to adolescents upon discharge from one 
hospital between 2015-2019. (Chapter 4) 
a. Evaluate variation in prescribed opioid dosages. 
This work identifies risk factors associated with non-medical use of prescription drugs in 
adolescents and characterizes opioid prescribing to adolescents upon discharge at one 
health system. Variations in both receipt and dosage of opioid prescriptions are evaluated. 
With a better understanding of the clinical and patient factors that are associated with the 
prescription of opioids at discharge, findings can inform continued development of safe 
prescribing practices for adolescents and allow for targeted education and intervention for 
patients receiving opioids. Well-informed prescribing can mitigate opioid-related risks, 
including possible future misuse of prescription medication, in this vulnerable population. 
This dissertation is one of the first projects to characterize prescribing patterns in the 
adolescent population based on patient and clinical factors while also examining variation 
in opioid dosage prescribed upon discharge. Further, this project is one of the first by 
nurse scholars to address opioid use. Nurses, engaged in all aspects of patient care, are 
important stakeholders in addressing opioids and associated outcomes. Nurses in acute 
care settings are responsible for pain assessment and therefore directly inform pain 
management. They are positioned to advocate for safe and appropriate approaches for 
their patients and often provide education on prescribed medications. Given the role of 
nursing in assessing, educating, and advocating for patients, nurses must be prepared to 






Drug overdoses resulted in the death of nearly half a million Americans since the year 
2000. In 2017 alone, 70,237 Americans died from an overdose, nearly 70% of which 
resulted from opioid overdose.4 While recent national attention has shifted from 
prescription opioids to the illicit use of opioids like fentanyl, the death rate from 
prescription-opioid overdoses nearly quadrupled between 2000 and 2014.2,6,7 In these 
years other outcomes like opioid related emergency room visits, opioid related 
admissions to substance abuse treatment programs, and rates of neonatal abstinence 
syndrome also increased.1-8 Young people were not immune as adolescents between the 
ages of 15 and 19 experienced a 91% increase in prescription opioid related overdoses.10 
It is suggested that prescribing rates, which are linked to these outcomes, leveled 
sometime between 2010 and 2012, with certain areas of medicine like emergency 
medicine and dentistry, reporting decreased rates.17,18 However, some evidence suggests 
that opioid prescribing to patients ages 0-17 has remained relatively stable for the past 
two decades, warranting a closer look at the medical use of these medications in this 
population. Regardless of the changing opioid prescribing rates, they remain powerful 
medications with significant benefits and risks.19 The current focus on opioids in the 
United States has generated increased attention to the medical use of opioids. However, 
this is not the first-time healthcare has been tasked to define and promote responsible use 
of prescription opioids, and it will not be the last. Opioids are amongst the oldest 
medications in medicine and humans throughout history have repeatedly examined their 
medical utility in the face of the associated adverse outcomes. Continued research to 
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elicit informed and evidence-based utilization of opioids in medicine will remain 
important for the health of the individual and the public.  
A Historical Perspective 
From at least 3400 BC, when the Sumerians cultivated the poppy plant, opium (and its 
derivatives) has been highly valued for its medicinal utility.20,21 Used for ailments 
including colic, alcoholism, cough, dysentery, and more, opioids provided physicians 
throughout history with the power of providing their patients with relief.22-25 In the 
United States, the introduction of the hypodermic needle enabled physicians to steward 
the already valued morphine into an easily abused, instant cure-all. This ubiquitous use of 
opioids in the later 19th century contributed to the nation’s first opioid epidemic.22 
Patients in the 19th century often expected their physician to provide injectable morphine. 
Many physicians, motivated to compete with other physicians for business, feared the 
repercussions of losing patient clients if they did not provide morphine. Physicians were 
the gatekeepers of the drug, and thus receipt of an opiate from a health care provider was 
a common mechanism of addiction.22,23 Eventually this liberal palliation was curbed by 
growing recognition of opioid use disorder, sophistication in medical treatments and 
diagnostics, government regulation, and more controlled prescribing.22,23 
The current opioid epidemic shares similarities with the past as treating patient 
symptoms and generating profit drove opioid use to new heights. In the mid 1990s, 
concerns arose amongst well-meaning clinicians that too many American’s were 
suffering from pain. The American Pain Society touted pain as the “fifth vital sign”, a 
perspective that quickly spread across health care.26 The Joint Commission also 
addressed pain by publishing pain management standards and emphasizing quantitative 
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pain assessments. Prescribers were charged with adequately managing pain and 
increasingly used opioids to meet the Commission’s pain management benchmarks.26 
The pharmaceutical industry contributed as well, amplifying and falsifying research 
findings to portray a low risk of addiction associated with prescription opioid 
medications. In sponsoring conferences and seminars, and generating reformulations, the 
industry ensured their products were prominent, easy to access, and highly profitable.26-29 
Starting in 1999 and peaking around 2012, rates of opioid prescribing and use increased 
across all ages. In this time frame, for example, the nation’s consumption of hydrocodone 
more than doubled, while consumptions of oxycodone increased by nearly 500%.2,6-8 
Despite the pharmaceutical industry’s claims, this surge in prescribing proved the 
inherent risks with broad use of opioid pain relievers as overdoses related to their use 
quadrupled during this time.2,6,7 Prescribing is thought to have peaked in 2012, when 259 
million prescriptions were written, creating a public supply of opioids large enough to 
medicate every adult in the United States every four hours for a month.7,9 
The widespread prescribing and consumption reached young populations, as well. 
From 1997 to 2012, a study utilizing a nationally representative sample of pediatric 
hospital discharge records found the annual rate of children hospitalized with opioid 
poisoning-related events increased by 165%.10,30 Adverse opioid related events increased 
in all children and adolescents ages 1 to 19 years old between 1997 and 2012. The 
researchers identified the largest increases were experienced by children aged 1 to 4 years 
and adolescents aged 15 to 19 years.30 Analysis of the National Poison Data System 
(NPDS) between the years 2000 and 2015 revealed that adolescents who presented for 
care with opioid exposure were up to five times more likely to experience serious adverse 
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outcomes compared to children in any other age group.10 This study also reported a 91% 
increase in fatal overdose deaths among teenagers 15-19, an increase the CDC finds 
concurrent with the increase in prescribing and drug related deaths in overall 
population.10,11 It is likely a number of these adverse outcomes can be attributed to a 
variety of events, such as the improper use of a medication prescribed to a child, or the 
child’s accidental exposure to an adult’s prescription medication. However, the study of 
NPDS demonstrated that more than two-thirds of the reported opioid exposures in 
teenagers were intentional exposures.10 This finding supports previous research utilizing 
NPDS which demonstrated unintentional exposures outnumber intentional exposures in 
every age group except ages 13-19.31 
Even though the prescribing of opioids has generally plateaued, adolescents are still 
regularly exposed, often through healthcare and sometimes through the diversion of 
medications prescribed to a peer or family member. Estimates suggest 25% of high 
school seniors have lifetime exposure to opioids through medical or non-medical 
means.12 From a public health perspective, it is important to note that any opioid 
prescribed to an individual outside of the inpatient setting is entering a community, and 
can impact any number of community members. Exposure from health care presents a 
target for education and intervention efforts to promote safe opioid use that other sources, 
like diversion, do not have. Research has shown that adolescents are particularly 
vulnerable to experiencing adverse outcomes related to opioids. These adverse outcomes 
can be long-lasting, even when opioid exposure occurs for medical reasons. This 
vulnerability is rooted in the significant development occurring in this stage of life. 
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Adolescence as a Key Development Period 
Adolescence is a period of rapid development in which the functional and biological 
processes of maturation interact with the social, cultural, and physiological environment 
to shape how an adolescent feels, thinks, and behaves.32-34 Operational definitions of 
adolescence often include specific age ranges or developmental milestones. For this 
dissertation adolescence is defined as the ages 10-19, aligning with the definition 
provided by the World Health Organization (WHO).35 Other definitions of adolescence 
can extend to age 26.32 These variations exist partly because adulthood has traditionally 
been marked by functional and financial independence, and changing familial 
responsibilities. These social roles, and the age at which they occur, can vary across time 
and culture.32 Regardless, a basic insight into some of the complex, neurological 
morphologies is required to understand why this period of life is risky in the development 
of problematic substance use while also being an opportunity for prevention and the 
cultivation of healthy behaviors, including safe use of prescribed opioids.  
Development of the prefrontal cortex is key to the risks for addiction in adolescence. 
Responsible for executive functions, it is the behavioral brake system enabling self-
monitoring, impulse control, and goal-directed behaviors. It is not fully developed until 
the third decade of life.25,36 In contrast, however, are the more developed subcortical 
limbic pathways primary in the brain’s reward system. When stimulated, these pathways 
create a rewarding experience for the adolescent, with dopamine as a major player. In 
addition to feeling pleasurable, the action of these pathways helps encode the memory of 
the reward, assigning it emotional value and allowing it to be recalled for use in future 
decisions. With a comparatively more developed reward system, an adolescent may be 
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unmotivated by small rewards, or rewards of no personal significance.25,36 In turn, they 
seek larger rewards, thus the observation that adolescents can be impulsive, risk-taking, 
and thrill seeking.37 While it was once thought adolescents were simply incapable of 
weighing risks and benefits like their adult counterparts, hence those characteristic 
behaviors, this is no longer a common stance. Adolescents do weigh risks and benefits in 
decision making processes, even with a developing prefrontal cortex. However, 
biologically, it is the rewarding and stimulating decisions that tip the scales. Substances, 
like opioids, are amongst the innumerable factors that can stimulate the brain’s reward 
center. 
In addition to the key elements of the prefrontal cortex and the reward systems, it 
must be acknowledged the whole brain is developing into its adult form. Through 
synaptic pruning, unnecessary neural connections are eliminated. Meanwhile, 
myelination results in faster and more efficient information flow across the brain.33 
Disruptions to these processes can be significant and may change the developing 
pathways. Drug and alcohol use impact the trajectory of this development, resulting in 
neural insults that may remain for life.34 It is known that substance use in adolescence can 
result in physical and microstructural changes in the brain. Opioids, just like other 
substances, interact with the dopamine pathways and influence developing neural 
connections.38 This is particularly salient when remembering that one in four high school 
seniors have an exposure to an opioid before graduation. This may partially explain why 
adolescents prescribed an opioid in high school are more likely to misuse opioids later in 
life.39 Receiving an opioid prescription by 12th grade increases the risk of future non-
medical use (misuse) by 33% by the age of 23, compared to those who did not receive an 
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opioid prescription.13 This physiological basis further explains why substance use 
disorders have significant roots in adolescent development. Importantly, the risk of 
developing a substance use disorder later in life decreases for each year substance 
initiation is delayed.25 
The vulnerability of adolescence presents risk to prescribing opioids in this young 
population. However, this period of development also presents opportunity to promote 
health behaviors for a lifetime. Continuing to understand how and why opioids are 
needed by adolescents and what factors may contribute to the misuse of opioids will 
inform evidence-based practice, contribute to knowledge needed to balance the benefits 
of these medications with their risks, and allow for well targeted intervention efforts. 
Opioids 
Opioids are analgesics including medications like oxycodone, morphine, fentanyl, 
hydrocodone, Vicodin, and diluadid. Opioids act on specific receptors (most commonly 
mu, kappa, and delta) located throughout in the body’s nervous system. When opioid 
binds to its receptor, a complex cellular signal transduction pathway is initiated that 
interrupts the transmission of pain and allows the release of dopamine, thus producing a 
strong analgesic and rewarding effect. Opioids do not increase the body’s pain threshold, 
nor do they completely block pain transmission. Rather, they decrease perception of pain 
while the increase in dopamine produces a feeling of euphoria.40 Effective in managing 
several types of pain, these medications have the potential for a number of serious 




Recently, the CDC, Surgeon General, state governments, and professional societies 
like the American Pain Society and the American Academy of Pain Medicine attempt to 
promote safe prescribing and guide the use of opioids.42-44 There are many guidelines 
targeting various adult populations and chronic pain. While these guidelines are a step in 
addressing the use of opioids, much more work is needed across patient populations to 
use opioids appropriately and manage pain effectively. Guidelines are not intended to 
replace clinical judgement, but rather supplement. In the face of national attention and 
attempts to guide prescribing, it is important to understand how opioids are currently used 
to better inform future clinical practice. The majority of research on this topic is in the 
adult population, which continues to find wide variation in how opioids are prescribed by 
time, patient characteristics (e.g. insurance, race, education, etc.), clinical characteristics 
(e.g. diagnosis, procedure), prescriber characteristics (e.g. specialty, licensure), and 
geography, even in the face of multiple guidelines.17,18,45-50 For example, in their analysis 
of IMS Health’s National Prescription Audit, Levy et al., found that nine medical 
specialties accounted for 84.3% of all opioid prescriptions between 2007 and 2012, with 
family practice, internal medicine, and general practice accounting for nearly half of all 
dispensed opioids. Pain medicine, surgery, and physical medicine/rehabilitation had the 
highest rates of prescribing in the same time period. Interestingly, pain medicine, surgery, 
and emergency medicine demonstrated the greatest decline in prescribing rates, and 
showed decline even before 2010, after which most specialties followed. They also found 
that non-physician prescribers (physician’s assistants and nurse practitioners) accounted 
for 11.2% of all dispensed opioids. These prescribers experienced above average growth 
in prescribing until stabilizing in 2010.25 Overall, this study states that the rate of opioid 
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prescribing increased between 2007 and 2012, with a noted decline after 2010. Variation 
is not just limited between specialties, as several studies have demonstrated variation 
within specialties. A study of patients enrolled Medicare Part D who received care at an 
emergency department of one hospital found substantial variation in opioid prescribing 
between physicians. Further, the intensity of a physician’s opioid prescribing was 
positively associated with increased probability of a patient becoming a long-term opioid 
user with one year.45 Similar variations have been reported for the rates of prescribing 
and the dosage prescribed for common surgical procedures, even in studies conducted in 
a single medical center.47,50 McDonald et al. also found significant geographic variation 
that are not attributable to population difference in prevalence of surgeries, injuries, or 
painful conditions.49 A disproportionate number of high prescribing counties were found 
in western and southern states, and Appalachia, although findings varied at the county 
level. Availability of physicians was found to be the strongest correlate of prescribed 
opioids. Other correlates included the proportion of the population that was non-white 
Hispanic or African American, uninsured, and living in urban areas.49 Guy et al reported 
similar findings, identifying lower educational attainment, higher rates of unemployment, 
higher Medicaid enrollment, and more physicians and dentists per capita as factors 
associated with high opioid prescribing.17  
Far less work is dedicated to younger populations, particularly adolescents. However, 
the existing research demonstrates similar variability.19 Unsurprisingly, data suggest 
opioid prescribing in children and adolescents becomes more common with increasing 
age.51 Two studies of pediatric patients showed that white patients consumed more 
opioids while hospitalized and were more likely to be prescribed an opioid.52,53 A 
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national study of ambulatory care settings found emergency departments (EDs) to be 
more likely to prescribe opioids to adolescent and young adult populations than other 
ambulatory settings.54 This study identified common conditions treated in the ED and 
warranting a prescribed opioid (dental disorders, broken clavicle, back pain) which 
supports previous studies identifying similar conditions.55,56 However, there was variation 
in opioid prescription dosage even for the identified common conditions.54 This finding is 
similar to the wide variation in prescribed dosage described in a study focused on 
pediatric and adolescent patients with sickle cell disease, a condition commonly requiring 
analgesics, discharged from the ED.57 
These findings show a continued need to understand opioid prescribing. Many of 
these studies include pediatric patients as well, creating an even larger gap in adolescent 
specific knowledge. It is known that adolescents are exposed to opioids through 
healthcare. This exposure comes with identified benefits and risks. However, 
understanding how opioids are prescribed in this population is necessary to evaluate and 
inform guidelines for evidence based clinical practice. 
Summary 
The use of opioids in healthcare significantly impact individual and public health. 
Increased focus on opioid use calls for in-depth analysis of patterns of opioid prescribing 
in healthcare. It is already known that exposure to drugs, including opioids, at a young 
age increases the odds of later problematic drug use.1,13 Adolescence is an important time 
in human development and presents valuable opportunity to promote safe prescription 
drug use. While increased attention to opioid use has generated a number of guidelines 
for safe prescribing, little is known about the current use of these drugs in adolescent 
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patients. Examination of the literature on adolescent prescription drug misuse, paired 
with descriptive work on how and why these drugs are prescribed to adolescent patients 
will contribute needed evidence for continued development of safe prescribing practices 
and future targets for intervention work. 
Chapter Aims and Methods 
Chapter 2 
Aim: Identify factors associated with adolescent non-medical use of prescriptions drugs. 
Method:  A systematic literature review was conducted in PubMed, PsycInfo, and 
Embase. Medical Subject Headings (MeSH) and key terms relating to adolescence, 
nonmedical prescription drug use, risk factors, and prescription drug classes were 
included to identify a wide range of citations. The Quality Assessment Tool for 
Observational Cohort and Cross-Sectional Studies from the National Institutes of Health 
(NIH) was used to evaluate the evidence included in this review. 
Chapter 3 
Aim: Characterize opioid prescribing to adolescents prescribed a pain medication at time 
of discharge from an admission of 48 hours or less. 
Hypothesis: There will be variation in the odds of opioid prescription by patient and 
clinical factors. Patient factors like age, race, and insurance will be significantly 
associated with the odds of receiving an opioid prescription upon discharge. Gender will 
not be a significant patient factor. Surgery, pain score, unit of discharge, and prescriber 




Method: A retrospective cross-sectional analysis of CHOP’s EHR data between 2015 and 
2017 was conducted. The sample of 2,180 was comprised of adolescents between the 
ages of 10 to 19 who received a pain-related prescription medication at time of discharge. 
Bivariate logistic regressions assessed the association of between identified variables and 
the receipt of an opioid prescription, the primary outcome of interest. Finally, a stepwise 
multivariate logistic regression was constructed to assess the relationship between the 
significant variables from the bivariate regression and the receipt of an opioid 
prescription. 
Chapter 4 
Aim 4.1: Evaluate trends in opioid prescribing to adolescents upon discharge from one 
hospital between 2015-2019.  
Aim 4.2: Describe variation in morphine milligram equivalents/day (MME) among 
adolescents prescribed an opioid upon discharge. 
Hypothesis:  
Both the proportion of adolescents leaving over time and dosage of prescribed opioids 
will decrease each year during the study period. There will be additional decreases after 
the implementation of Pennsylvania’s safe prescribing guidelines.  
Method: This cross-sectional retrospective study utilized EHR data from CHOP to  
obtain a random sample of 9,176 eligible patient visits between 2015-2019. The sample 
was comprised of adolescents between the ages of 10 and 19 who were discharged from 
an inpatient unit after an admission of 5 days or less. Four outcome groups were 
identified based on analgesics prescribed at discharge: 1) those discharged without pain 
medication; 2) those discharged with non-opioid pain medication only; 3) those 
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discharged with an opioid medication only; and 4) those discharge with both an opioid 
and a non-opioid medication. After describing the sample, multinomial logistic regression 
was used to evaluate the associations between patient factors, clinical factors, time, and 
each outcome group. To address Aim 4.2, a sub-group analysis was conducted using all 
adolescents in 4.1 flagged as receiving an opioid prescription upon discharge. Opioid 
dosage was converted to morphine milligram equivalents/day (MME) to allow for 
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Chapter 2  
Risk factors associated with adolescent nonmedical prescription drug use: 
A rapid review of the literature 
Abstract 
Nearly 2.5 million adolescents in the United States have misused prescription drugs, and 
this young population constitutes one third of all new abusers of prescription drugs. 
Nonmedical use of prescription drugs is second to only marijuana amongst illicit 
substance use. In addition to having immediate health effects, this problematic use can 
impact health across the lifespan. Addressing, and ultimately preventing nonmedical use 
of prescription drugs requires an understanding of the risk factors that contribute to its 
initiation in adolescence. A literature review was conducted utilizing PubMed, PsycInfo, 
and Embase. Inclusion criteria were employed to select articles focused on the risk 
factors associated with adolescent nonmedical use of prescription drugs. Articles 
identified by this search strategy discuss demographic characteristics, social environment 
factors, and health factors. The body of the largely cross-sectional evidence demonstrates 
some consistent findings but highlights a need for more standardized definitions and 





Nearly 2.5 million youths in the United States (U.S.) aged 12-17 have misused 
prescription drugs in their lifetime. This represents 10% of the U.S. adolescent 
population, a group that constitutes one third of all new abusers of prescription drugs.1 
One in five high school students have used a prescription drug non-medically, with 
opioid misuse being most common.1 This is a particularly salient finding as the United 
States continues to grapple with an unprecedented opioid crisis. Nationally, nonmedical 
prescription use peaked in 2010, largely driven by the overprescribing of opioids.2 This 
trend has been slowly declining in the adult population, yet remains more stable in the 
adolescent population.3 In fact, nonmedical use of prescription drugs (NMUPD) is second 
to only marijuana use amongst illicit substances nationwide.1 Addressing, and ultimately 
preventing NMUPD requires a continued commitment to understanding the risk factors 
that contribute to its initiation in adolescence.  
Much of what is known about NMUPD focuses on the adult population. Indeed, 
substance use disorders manifesting in adulthood have significant roots in adolescence, 
with 90% of cases beginning with a drug exposure in the teenage years.4,5 Similarly, early 
initiation of NMUPD, particularly before the age of 18, significantly increases the risk of 
continued problematic use extending into adulthood.6-9 These long-term outcomes are in 
addition to the more immediate effects of NMUPD which can include various deleterious 
neural and physiological impacts, facilitation of polysubstance use (including the use of 
other illicit drugs such as cocaine and heroin), impaired decision making, risky behaviors, 
overdose, and potentially death.7,10,11 While this knowledge derived from adults is both 
informative and valuable, it does not necessarily provide relevant information about 
adolescence, a period of rapid growth, increased experimentation, and emerging 
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independence. Research continues to highlight adolescence as a particularly unique and 
vulnerable time in human development.9 It stands that adolescents may experience risk 
factors for NMUPD, and its progression, differently than their older counterparts. This 
considered, literature focusing on this particular pattern of drug use in the younger 
population remains scant. 
In addition to the significant vulnerability characterizing adolescence, the challenge 
of addressing NMUPD is amplified by the medical value of the most commonly misused 
prescription drugs: opioids, stimulants, and sedatives. An adolescent’s first exposure may 
arise from a necessary treatment or, more commonly, from family members or peers with 
legitimate prescriptions.12 Therefore, healthcare professionals are charged with balancing 
the medical necessity of these prescriptions with the risks, a task not associated with the 
use of other illicit substances. To promote appropriate use of these medications, and to 
contribute to the development of informed prevention strategies, this review seeks to 
synthesize the current literature on risk factors associated with NMUPD during 
adolescence. 
Method 
For this review, adolescence was defined as ages 10 to 19, consistent with the World 
Health Organization (WHO).13 Nonmedical use of prescription drugs was operationalized 
as the use of medications prescribed for another individual, not as prescribed, or the use 
of a medication only for the feeling or experience it causes (i.e. to get high). A literature 
review was conducted in PubMed, PsycInfo, and Embase to identify a wide range of 
citations (Figure 2.1). Medical Subject Headings and key terms relating to adolescence, 
nonmedical prescription drug use, risk factors, and prescription drug classes were 
included in the conduct of this review. This approach yielded 1820 articles. Articles 
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needed to meet the following criteria for inclusion: (1) sample population within ages 10-
19, (2) NMUPD as a dependent variable, (3) measure of risk included in statistical 
analysis, and (4) include any or all of the prescription categories of interest (opioids, 
stimulants, and sedatives, Table 2.1). Exclusion criteria included: (1) research on the 
effects of NMUPD (2) articles not written in English (3) sample populations outside the 
United States (4) college and/or university samples (5) research on treatments or 
interventions, and (6) commentaries. From the original yield, 133 studies were reviewed 
in full, and 32 met criteria for inclusion in this synthesis.  
Study Characteristics 
The final sample includes 3 longitudinal studies and 29 cross-sectional studies. The 
majority of these articles are secondary analyses, predominantly using data from the 
National Survey of Drug Use and Health (NSDUH), and the Monitoring the Future study 
(MTF). Sponsored by the Substance Abuse and Mental Health Service Administration 
(SAMHSA), the NSDUH has provided nationally representative samples of 
approximately 70,000 participants annually since 1971. Respondents ages 12 and older 
provide information on alcohol and tobacco use, illicit drug use (including NMUPD), and 
mental health. The MTF surveys approximately 50,000 8th,10th, and 12th grade students 
annually. Initiated in 1975, this study provides information on attitudes, beliefs, and 
behaviors of youth in the United States. Descriptions of other parent studies from which 
data was analyzed by articles included in this review are provided in Table 2.2. Details of 
the all studies included in this review are provided in Table 2.3. All statistics presented 
are derived from the original manuscripts with 95% confidence intervals (CI) and p-




The Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies from 
the National Institutes of Health (NIH) was used to evaluate the evidence included in this 
review. According to these guidelines, articles were graded as good, fair, or poor (Figure 
2.2). Studies rated good or fair are susceptible to bias but not so much as to invalidate 
findings. The fair category may be broadly interpreted, with articles of this score varying 
in their strengths and weaknesses. This set of guidelines recommends articles rated as 
poor, signifying significant methodological issues, be excluded from inclusion unless no 
other evidence is necessary. However, in this present review, no articles were rated as 
poor (Table 2.1). 
The most rigorous evidence comes from experimental or quasi-experimental designs. 
However, the Quality Assessment Tool for Observational Cohort and Cross-Sectional 
Studies was selected because the literature addressing risk factors for substance use is 
overwhelmingly cross-sectional. The selection of this criteria reflects the decision to 
acknowledge the hierarchy of study design while recognizing the reality of this field of 
research. Because randomization is nearly impossible for community level research, this 
is an appropriate approach.14 
Results 
Race 
Nearly every study in this review addressed race in an effort to characterize and describe 
the adolescent population engaging in NMUPD. Generally, studies assert that this pattern 
of drug use is most prevalent in White adolescents and less prevalent in adolescent 
populations identifying as African American, Asian, Native American, and other 
ethnicities.15,16 Several studies further investigated race as a risk factor associated with 
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NMUPD. An analysis of nationally representative data from the NSDUH found that 
compared to Black adolescents, White adolescents were over four times as likely to 
report past year opioid misuse (Odds Ratio [OR]=4.32, p < 0.001).11 The conclusion that 
white adolescents have increased odds of nonmedical opioid use was supported by 
additional studies utilizing different samples from the NSDUH, as well as respondent 
data from MTF and YRBSS.12,17-19 However, the association between race and opioid use 
was not always significant.20,21 In an analysis using multivariate models to estimate 
associations separately for demographic, psychosocial, and theoretical risk factors, race 
did not emerge as a significant variable. In fact, very few demographic characteristics 
were associated with opioid misuse, with psychosocial factors (such as delinquency) and 
theoretical factors (such as school and parent bonds) emerging as more significant.20 
While the conclusions from these studies differ, each were scored as good using the NIH 
grading criteria for observational studies. 
Fewer studies focused on non-opioid NMUPD. Two studies of  national samples 
found that White adolescents, compared to adolescents who reported their race as non-
white, had higher odds of reporting nonmedical stimulant use.22,23 Similarly, Boyd et al., 
found in a Michigan based sample that compared to Black participants, White 
participants were twice as likely to report using another person’s anxiolytic medication 
(OR=2.52, CI: 1.25-5.08, p < 0.05).24 These studies also scored as good according to the 
grading criteria. 
While the above studies examined drug use by class, some combined the drug 
categories of interest into a single composite variable. Even under these conditions, it 
appears White adolescents present higher odds for overall NMUPD.15,16 McCauley et 
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al’s., study, scored as good, support African American adolescents having significantly 
lower odds of NMUPD (OR=0.44, p < 0.01) in a nationally representative sample.15 
Viana et al., in a study scored as fair, reported similar findings regarding African 
American adolescents (lower odds) in a Mississippi sample, adding that Hispanic, Asian, 
and youth who indicated “other” as their race, were comparable to White adolescents in 
risk.16 
Gender 
Two articles, scored as good according to NIH grading criteria, and utilizing data from 
MTF, found gender to be a significant associate of nonmedical opioid use.11,18 One of 
these analyses demonstrated male high school seniors were not only one and half times 
more likely (OR=1.56, p < 0.001) to report nonmedical use of opioids, but they were also 
more likely to report frequent use (defined as more than 10 times in the past year) 
(OR=2.48, p < 0.001).11 Similarly, the second study demonstrated females had lower 
odds than males (OR=0.79, p < 0.001).18 However, a sample of pooled NSDUH data 
found females at increased odds of using opioids non-medically (OR=1.27, CI: 1.17-1.38, 
p< 0.001).12 
Results were also conflicting when examining stimulant use by gender. Two studies, 
both utilizing NSDUH data, examined this phenomenon. Analysis of pooled 2003-2009 
data reported females were more likely than males to report stimulant use (OR=1.49, 
CI:1.19-1.86, p < 0.001) while analysis of 2002 data demonstrated no gender differences 
in stimulant use.12,25 Similar to the findings regarding opioid use, each of these articles 
scored as good using the NIH grading criteria, despite their conflicting conclusions. 
Finally, the role of gender was also studied using a composite NMUPD variable. 
McCauley et al., found no significant difference between genders in a nationally 
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representative sample.15 Similarly, Collins et al., did not find a significant difference in 
NMUPD by gender.26 However, the Collins et al., study utilized a non-nationally 
representative sample and rated as fair using the NIH guidelines, while the McCauley et 
al., study rated as good. In contrast, Ayres et al found lower odds of NMUPD compared 
to males in their analysis of nationally representative YRBSS data (OR=0.71, CI: 0.62-
0.82, p < 0.01).19 These results suggest that gender may impact NMUPD differently by 
drug class. 
Age 
Very few studies in this review examined increasing age as a risk factor. When it was 
discussed, age was consistently associated with higher odds of NMUPD. An analysis of 
NSDUH data by McCauley et al., demonstrated risk increased with age.15 Compared to 
adolescents aged 12-13, participants aged 14-15 and 16-17 were more likely to report 
NMUPD (OR =4.21, p < 0.001; OR=8.02, p < 0.001, respectively).15 Studies from 
different samples of the NSDUH had similar findings.17,27 This association remained in 
two separate studies, one investigating opioids and stimulants, and one investigating 
opioids alone.12,20 However, two different analyses from the YRBSS did not find 
significantly increased odds in the non-medical use of opioids with increasing age.21,28 
Further, a study on adolescents in an Appalachian county did not find a significant 
association between any NMUPD and older age.26 This study scored as fair using the 
NIH criteria, however, all other articles scored as good and included nationally 
representative samples. 
Rurality 
Two studies examined rurality as a main variable of interest, finding it associated with 
higher odds of NMUPD. An analysis of data from the 2008 NSDUH found rurality to be 
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associated with increased risk of nonmedical prescription drug use, even when adjusting 
for sociodemographic characteristics, health status, and other lifetime substance abuse 
(OR=1.26, CI:1.01-1.57).7 Monnat & Rigg also used NSDUH data, pooled from the 2011 
and 2012 surveys, to examine the role of rurality in prescription opioid misuse, 
specifically. Rural adolescents had 35% greater odds of prescription opioid misuse than 
their urban counterparts (OR=1.35, p = 0.025).17 These results support data from the 2002 
MTF survey.11 Each of these studies utilize national samples and score as good using the 
NIH Quality Assessment Tool, but there are some differences. The NSDUH studies 
measure demographic location as urban/large metro, suburban/small metro, and 
rural/nonmetro. MTF employs demographic location as a dichotomous variable. 
Additionally, unlike the MTF article, the studies using the NSDUH focused on rurality as 
a main variable, thus resulting in a more thorough discussion of rural life and drug use. 
The authors, Monnat & Rigg, discuss different risk factors associated with living in 
different geographic areas. For example, according to their analysis rural adolescents are 
protected by some features of rural life (less peer drug use, less access to drugs), but 
experience other risk factors such as less risky attitudes and more criminal involvement.17 
These findings highlight the complex interaction of risk factors contributing to NMUPD. 
Mental Health 
Mental health was associated with NMUPD. NSDUH data was used to explore the 
relationship between past year major depressive episode (MDE) and opioids. While past 
year MDE was not significantly associated with opioid misuse, both subthreshold 
dependence and dependence were, suggesting the relationship between MDE may be 
stronger with higher levels and patterns of nonmedical opioid use (OR=1.46, p < 0.05; 
OR=1.77, p < 0.05).29 The finding that nonmedical use may increase with symptom 
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severity was also true in a sample of Mississippi youth.16 Another NSDUH study found 
past year mental health treatment service utilization (used as a proxy measure of mental 
health) to be associated with increased odds of nonmedical use of pain relievers for 
females, but not males (OR=1.53, p < 0.001).27 Finally, an analysis from McCauley et al., 
of nationally representative data did not reveal MDE to be a significant risk associate of 
NMUPD.15 This study, unlike those associated with the NSDUH, focused on a composite 
variable of NUMPD. These results suggest that mental health may impact the misuse of 
prescription drugs differently by drug class and gender. 
Ayres et al similarly study the role of depression with their dichotomous depressive 
symptom variable, assessed by asking “[d]uring the past 12 months, did you ever feel so 
sad and hopeless almost every day for two weeks or more in a row that you stopped 
doing some usual activities?” Presence of depressive symptoms was associated with 
increased odds of NMUPD (OR= 2.49, CI: 0.54-0.86, p < 0.02). In this study, only 
opioids and stimulants were included.19 Two additional analyses from the same parent 
study, focusing on opioids, reported similar findings. As expected, those endorsing 
depressive symptoms had almost double the odds of non-medical use of opioids when 
compared to their peers not endorsing depressive symptoms.21,28  
Five studies examined the association between traumatic event exposure and 
NMUPD. McCauley et al., found both lifetime post-traumatic stress disorder and 
witnessed violence to be associated with increased odds of NMUPD (OR=2.25, CI: 1.39-
3.63, p < 0.001;OR=3.76, CI: 2.65-5.33, p < 0.001, respectively).15 Another study of 
female respondents in Michigan found those who had experienced sexual assault were 
four times as likely to report any NMUPD than those who had never experienced sexual 
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assault (CI: 1.4-13.0, p < 0.01).30 This association remained significant when opioid use 
and sedative use were analyzed separately (OR=5.4, CI: 1.8-16.1, p < 0.01; OR=5.7, CI: 
0.9-37.6, p < 0.05). Clayton et al., examined the association of dating violence 
victimization on a composite NMUPD variable including opioids and stimulants. Dating 
violence victimization (DVV) was divided into three categories: sexual, physical, and 
both physical and sexual. DVV was assessed with two questions: 1) Physical DVV: 
“During the past 12 months, how many times did someone you were dating or going out 
with physically hurt you on purpose and; 2) Sexual DVV: “During the past 12 months, 
how many times did someone you were dating or going out with force you to do sexual 
things that you did not want to do?”. In males, sexual DVV only and both physical and 
sexual DVV were associated with NMUPD (aPR= 1.61, CI: 1.21-2.17). Among female 
students, physical DVV only (aPR= 1.43, CI: 1.03-1.99) were significantly associated 
with NMUPD. In a sample of lesbian/gay/bisexual students, De Pedro et al also found a 
significant association between non-medical use of opioids and physical violence (OR= 
1.10, C: 1.08-1.12, p < 0.01).31 While these findings are not comparable to those directly 
related to MDE, violence and sexual assault were researched in the context of mental 
health.  
Only one study examined the relationship between adverse childhood experiences 
(ACEs) and NMUPD. ACEs are traumatic stressors experienced in childhood that may 
have an impact on numerous outcomes later in life. The Minnesota Study Survey (MSS) 
assesses ACEs with six questions addressing household substance use, verbal abuse, 
physical abuse, parental intimate partner violence, sexual abuse, and parental 
incarceration. Forster et al found that for every additional ACEs there was a 56% increase 
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in the non-past year medical use of stimulants (OR=1.51, CI: 1.46-1.56, p < 0.001), a 
47% increase in the use of opioids (OR=1.47, CI: 1.42-1.52, p < 0.001), and a 52% 
increase in the use of tranquilizers (OR=1.52, CI: 1.45-1.59, p < 0.001).32  
Risky Behavior and Delinquency 
Risky behavior and delinquency were consistently associated with increased risk of 
reporting NMUPD. King, Vidourek, & Merianos, in a study rated as good, characterized 
risky behavior to include skipping school, getting in trouble with the police or in school, 
and being involved with a gang.33 Compared to adolescents engaged in low levels of 
risky behaviors, those involved in high levels were four times more likely to report 
NMUPD (OR=4.12, CI: 3.72-4.50, p < 0.001).33 McCabe, Boyd, & Teter demonstrated a 
similar relationship between similarly defined risky behavior and nonmedical use of 
OxyContin® and Vicodin®.11 Another study found being arrested two times or more 
(compared to never being arrested) was significantly associated with nonmedical pain 
reliever use (OR=2.19, CI: 1.33-3.61, p < 0.01).27 Ford & Rigg further explored this 
relationship by race (White, Black, and Hispanic) in a MTF sample, and found 
delinquency to be significant in each group (OR=6.05, CI: 4.29-8.53, p < 0.05; OR=3.65, 
CI: 2.00-6.68, p < 0.05, OR=2.45, CI: 1.46-4.13, p < 0.05, respectively).20 
Past Drug Exposure 
Past drug exposure was associated with increased odds of NMUPD in every article in 
which it was a variable. Studies analyzing data from both the NSDUH, MTF, and 
YRBSS found that past use of other substances such as tobacco, alcohol, and marijuana, 
and past use of other prescription drugs were associated with increased risk for reporting 
the nonmedical use of opioids.21,28,34,35 Further, Wu, Pilowsky, & Patkar examined the 
risk of nonmedical opioid use associated with age of first alcohol use, inhalant use, and 
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marijuana use by gender. They found past use of these substances to be significantly 
associated with nonmedical use of opioids across gender and age groups.27 Interestingly, 
research investigating polysubstance use by gender found recent marijuana use to be the 
strongest correlate of nonmedical opioid use in males (OR=9.3, CI: 5.0-17.5, p < 0.05) 
while recent alcohol use was the strongest correlate for females (OR=5.3, CI: 2.5-10.9, p 
< 0.05), which again highlights how drug use patterns may be influenced by multiple risk 
factors such as gender and concurrent substance use.36 NSDUH data also showed 
significant associations between the use of cigarettes, alcohol, marijuana, and inhalants 
and nonmedical use of stimulants.12 
Past substance use also remained significant when the drug categories of interest were 
combined for one NMUPD variable but there was some variation in which substances 
were included in analyses as well as which presented the highest risk. NSDUH data 
found significant increases in odds of reporting any NMUPD with use of cigarettes, 
alcohol, marijuana, and cocaine or inhalants. Of these substances cigarettes had the 
lowest odds (OR=2.34, CI: 1.89-2.89, p < 0.001), while cocaine or inhalants were most 
significant (OR=3.88, CI:3.11-4.82, p < 0.001).37 Another study of nationally 
representative data combined other illicit substances (cocaine, heroin, marijuana) and 
club drugs (ketamine, methamphetamine, ecstasy) for analysis. Lifetime use of any of 
these drugs was significantly associated with NMUPD (OR=5.24, CI: 3.52-7.80, p < 
0.001). The relationship was also significant with lifetime binge drinking (OR=1.62, CI: 
1.04-2.52, p=0.03) and lifetime alcohol abuse (OR=2.40, CI: 1.56-3.68, p < 0.001).15 
Few studies investigated the role of legitimate medical exposure to prescription drugs. 
One study focused on sleeping medications and anxiolytics found medical exposure was 
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associated to nonmedical use of the prescribed medication. Specifically, adolescents with 
a recent medical exposure (defined as during the 3-year study period) to a sleeping 
medication were six times more likely to engage in nonmedical use (OR=6.40, CI:2.78-
14.78, p < 0.001) while those prescribed an anxiolytic were nine times more likely to use 
anxiolytics non-medically (OR=9.06, CI:4.26-19.26, p < 0.001).24 This study, one of the 
few longitudinal designs in the sample, has a good score according to the NIH guidelines. 
Additionally, this study demonstrated that cumulative medical exposure was also 
significantly associated with NMUPD. Receiving a prescription for sleep medications or 
anxiolytics at least once for two or three years was associated with significant increases 
in risk of misusing each medication compared to adolescents who were prescribed 
medications for one year (OR=5.37, CI:2.58-11.20, p < 0.001; OR=3.86, CI:1.71-8.67, p 
<0.001). However, a study from the MTF did not find a significant risk of nonmedical 
use associated with medical use of opioids.38 In addition to studying a different drug 
class, this study did not focus on temporality as the previous study. This may suggest risk 
derived from medical exposure may vary by drug class and time.  
Family Factors 
Several factors related to family life emerged from the literature including parental 
respect, parental disapproval, parental bonds, and family income. In one of the few 
longitudinal studies included in this review, Tucker et al., assessed parental respect using 
a four-item scale that included the importance of honoring, respecting, caring for one’s 
parent(s), and striving to be a good person. This study found higher parental respect was 
associated with lower odds of initiating NMUPD (OR=0.60, CI: 0.51-0.71, p < 0.05).39 A 
separate study by Collins et al., assessed adolescents’ perceptions of parental disapproval. 
While this study scored fair according to the NIH criteria (compared to the previous 
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study’s good score) it too highlights the important role of parents, as parental disapproval 
was associated with less risk of NMUPD (OR=0.49, CI: 0.4-0.7, p < 0.001).26 However, 
an analysis of a school-based study in Kentucky did not find a significant relationship 
between parental disapproval and the non-medical use of opioids specifically.40  
Less clear, however, is the role of parental presence. Presence of parents is not 
measured by perception of the relationship, as above, but by understanding which, if any, 
parents reside with the adolescent respondent. An analysis of data from the 2009-2013 
MTF surveys found that residing with two parents was protective against nonmedical 
opioid use when compared with respondents living with zero or one parent(s) (OR=0.70, 
CI:0.66-0.74, p < 0.001).38 Similarly, data from rural NSDUH respondents living in a 
two-parent home were 32% less likely to report any NMUPD (OR=0.68, CI: 0.53-0.88, p 
< 0.001).7 Another study of NSDUH data (which included all respondents, not solely 
rural respondents) showed parental presence to be significant in univariate analysis, but 
not the final multivariate analysis.37 Additionally, no significant association was found 
between parental presence and NMUPD in a study of Mississippi adolescents.16 These 
conflicting findings resulting from varied samples highlight the need to further 
investigate the role of parental presence. They suggest that other variables (such as 
rurality) may mediate this relationship.  
There were limited findings regarding the relationship between family income and 
NMUPD. McCauley et al., with a nationally representative sample, found no significant 
relationship between family income and NMUPD.15 Nakawaki & Crano, using NSDUH 
data, investigated opioids and stimulants. They found no significant relationships 
between family income and nonmedical stimulant use, but did find a significant 
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association with nonmedical opioid use. Adolescents from families with an annual 
income of less than $20,000 and $20,000-$49,000 were more likely to report nonmedical 
use than adolescents with a family income of $75,000 or higher (OR=1.50, CI:1.22-1.84, 
p < 0.001 and OR=1.41, CI:1.21-1.50, p < 0.001).12 Each of these studies were scored as 
good according to the grading criteria. 
School Factors 
School factors manifested as grade performance, grade level and relationships. Ayres et 
al., found that compared to students in 12th grade, students in 9th and 10th grades were less 
likely to engage in nonmedical use, which they operationalized as a composite variable 
containing different drugs classes (OR=0.53, CI: 0.44-0.65, p < 0.0l; OR= 0.77, CI: 0.77, 
CI:0.63-0.92, p < 0.01).19 One study, from the NSDUH, demonstrated increased risk of 
NMUPD associated with reporting D’s or lower (OR=1.56, CI: 1.23-1.96, p < 0.001).37 A 
study from the MTF focusing on OxyContin® and Vicodin® had a similar finding 
(OR=2.38, p < 0.001), as did a study of the YRBSS.11,28 A study in Appalachian youth 
did not find a significant association between grades and nonmedical prescription drug 
use, but did find that greater school commitment resulted in lower odds of reporting 
NMUPD.26 This study scored as fair using NIH criteria, however, a secondary analysis of 
NSDUH by J.A. Ford which scored as good revealed a similar relationship with school 
bonds and NMUPD (OR=0.77, p < 0.001).41 In a sample of lesbian/gay/bisexual students 
in California, De Pedro et al also found school to be protective. Students reporting school 
connectedness had lower odds of non-medical use of opioids (OR=0.75, CI: 0.69-0.82, p 
< 0.01) as did those who reported adult support at school (OR=0.88, CI: 0.83-0.94, p < 
0.01). Together, these findings suggest school factors, particularly those relating to 




Peers were consistently associated with NMUPD, though surprisingly it was one of the 
least discussed factors in this review. The MTF survey asks respondents about peer 
marijuana use and an analysis found seniors who reported prevalent peer marijuana use 
were over six times more likely to report using OxyContin® and/or Vicodin® non-
medically (OR=7.53 and OR=6.57, p < 0.001).11 A study of data from adolescents in 
Kentucky also found increased odds amongst those reporting non-medical use of opioids 
by peers (OR=1.74, CI: 1.57-1.95, p < 0.001).40 Collins et al., found a significant 
association between friend’s use of drugs and respondent reporting of any NMUPD 
(OR=1.48, CI: 1.2-1.8, p < 0.001), though this study scored as fair.26 Similarly, a study 
scored as good reported having close friends who have tried Adderall® increased the odds 
of nonmedical stimulant use (OR=8.67, CI: 5.78-13.02, p < 0.001).22 León et al., 
analyzing 2011 MTF data, found having access to stimulants was associated with 
subsequent higher odds of misuse (OR=4.3, CI: 3.1-6.0, p < 0.001).23 Unsurprisingly, 
respondents who reported being offered alcohol, cigarettes, or marijuana were more 
likely to also report NMUPD (OR=5.65, CI: 3.90-8.18, p < 0.05).39  
Discussion 
This review identified and discussed several risk factors associated with NMUPD 
including race, gender, age, rurality, mental health, risky behaviors, previous drug 
exposures, as well as family and peer influence. Discussing these results within the 
themes of demographic characteristics, social environment factors, and health factors 




Demographic characteristics were frequently discussed but with varying significance. 
Race was commonly cited as a predictor of NMUPD, but only two studies controlled for 
other sociodemographic characteristics when assessing its impact.18,20 Most studies 
started with bivariate analyses to inform multivariate logistic regression, but few 
provided enough information on the multivariate regression approaches to directly 
compare results across studies.3,12,16,18,22 In general, White adolescents were found to be 
at increased risk for NMUPD across drug classes. However, racial differences were not 
always significant and studies investigating opioid use and stimulant use in particular 
suggest that differences may be partially explained by the increased access White 
adolescents have to opioid or stimulant prescriptions due to their health care 
coverage.3,12,16,18,22 Further, as Conn and Marks highlight, race alone is not a sufficient 
mechanism to predict NMUPD, but rather represents a marker of underlying social and 
environmental factors.3 More needs to be understood to determine the relevant 
mechanisms that contribute to between group differences related to race. These 
differences are not necessarily explained by income, which is sometimes suggested, as 
higher income was not found to be a consistent risk factor.15,18 Other possible factors, 
such as social and cultural experiences related to demographic characteristics, were 
largely unexplored in this review but warrant attention. The studies discussing gender 
presented similar issues and a lack of consistent findings. This is at least partially related 
to varied methodological and statistical approaches. However, it may be more important 
to explore gender in the context of other factors. As demonstrated in this review, risk 
factors like mental health, experience of trauma or violence, concurrent substance use, 
and substance use patterns can vary by gender.12,21,25,27,30,31,36 This may suggest gender, 
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similar to race, is a marker for other factors and not solely a risk factor in itself. 
Motivations and desired effects from NMUPD, which is discussed in the adult focused 
literature, is not discussed thoroughly in this review. These factors may interact with 
gender in varied ways to influence NMUPD among adolescents. 
These findings highlight the complex interaction between risk factors. Race and 
gender can vary by drug of interest and by influences experienced by individuals, as 
discussed previously. While reporting demographic factors help characterize and describe 
NMUPD, results from this review suggest demographic characteristics are inextricably 
linked with the context of the individual. This idea is further supported by the findings 
associated with rurality. Compared to their urban counterparts, rural adolescents have 
higher odds of reporting NMUPD.7,17 The studies focused on geography suggest 
adolescents living in rural areas experience distinctive features of rural life.17 While some 
features, like lower reporting of peer substance use and less access to illicit drugs, buffer 
against NMUPD, other factors simultaneously increase risk. Monnat & Rigg found 
criminal behavior (discussed as delinquency in this review), lower perceived substance 
use risk, and ED utilization to be robust mediators of opioid misuse, all of which are 
more commonly experienced by rural adolescents. Past MDE, drug access, and peer 
substance use are also associated with higher odds of reporting opioid misuse, however, 
rural adolescents are less likely than urban adolescents to report these conditions. These 
findings were consistent across analyses, even when controlling for other 
sociodemographic characteristics, income characteristics, and substance use history.7,17 
Discussion of such distinctive features, and possible interactions, were noticeably lacking 
from many of the analyses focused on race and gender and other demographics. These 
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results highlight that demographic characteristics like race, gender, income, and rurality 
are relevant in the development of NMUPD in adolescents. However, the studies 
included in this review do not reveal how these characteristics interact with other 
demographic factors, or how they both influence and are influenced by contextual factors, 
like school, peers, family, cultural values, and more. Understanding these factors will 
have implications on how to prevent and address NMUPD from more informed 
perspectives.  
Social Environment Factors 
In addition to demographic characteristics, results from this review addressed some of the 
social environments, like peers, school, and family, that may contribute to NMUPD. Peer 
influence, including peer substance use and peer participation in the drug economy, 
contribute to the risk of NMUPD.11,16,26,34,40 Not surprisingly, adolescents who reported 
either peer factor were at increased risk of engaging in NMUPD. These factors were not 
explored in depth, though Tucker et al., discuss that such negative interactions may 
reflect interpersonal problems.39 This further highlights how multiple underlying 
individual characteristics can contribute to one measured risk factor. The role of peers, 
and the larger community surrounding adolescents, should continue to be explored to 
better understand these influences on adolescent NMUPD, as few studies included in this 
review addressed these issues. 
School measures included school performance, grades, and relationships. While 
grades are a commonly collected and more objective variable, measures such as school 
commitment are more subjective and need to be consistently measured if studies are to be 
compared. Few studies examined school factors, and each adopted a different approach. 
Three studies showed association between grades and NMUPD, while one study 
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contradicted these findings.11,26,28,37 Given the cross-sectional nature of these studies, 
more information is needed to understand how grades and adolescent drug use impact 
each other. Three studies examined the more subjective school bonds and commitment 
and suggest these relationships may be significant. However, school bonds and school 
commitment are distinct variables, and more research is needed to elucidate the role each 
play in NMUPD. Additionally, articles in this review do not describe if and how peers 
and school may intersect. For example, it may be of use to future intervention work to 
understand what opportunities exist in schools to engage in the drug economy and how 
this aspect of the school environment impacts NMUPD. The lack of discussion and 
consistency surrounding school factors in this review is surprising considering much of 
what is known about youth drug use is derived from the school based MTF study. It is 
also worth noting that school-based measures cannot account for students who are absent 
or do not attend school. Understanding the role of school not only in those who attend, 
but those who do not, will continue to elucidate the risks associated with school and 
NMUPD.  
The factors relating to family life exhibit similar difficulties as school factors. 
Parental respect, parental disapproval, and parental bonds appear to be associated with 
NMUPD and have some protective qualities.26,39-41 However, results regarding 
associations between physical parental presence and NMUPD appear to be more 
mixed.7,16,18,37 Again, these results consist of both subjective and objective measures and 
more research is needed to further develop these concepts. While this review 
demonstrates that family can play a role in adolescent NMUPD, more is to be understood 
about the relationships between these factors. For example, further exploring the role of 
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family life in relation to other identified risk factors including (but not limited to) rurality, 
school performance, mental health, and exposure to violence will further inform the 
context in which NMUPD develops. 
Health Factors 
The remaining factors addressed in this review are associated with health and health 
behaviors. Risky behavior and delinquency were associated with NMUPD. While this 
was a consistent finding in this sample of studies, there was variation in the definition of 
these behaviors. Because the majority of studies were secondary analyses, researchers 
were bound to the parent study method of data collection. This means they were unable to 
differentiate between risky behaviors, or further delineate the possible interactions 
between risky behavior, the role of peers in negative behavior, and shared risk factors 
between risky behavior and illicit drug use. For example, some studies defined 
delinquency by interaction with gangs or police, while others based delinquency on 
negative school interactions, such as skipping school or expulsion, with interactions with 
peers not included.11,33 Additionally, while articles in this review address risky behavior 
and delinquency, the difference between these two factors remains unclear and may 
further reflect inconsistency in the naming and measuring of variables. No study clearly 
differentiated between the two, and delinquency was often characterized by risky 
behaviors. The role of peers, which may influence delinquency or engagement in the drug 
economy, was not thoroughly addressed in this context and was more likely to be 
discussed as separate risk factors. Because of this, it is not clear how individual 
characteristics and social factors interact to impact risky behaviors. As with other risk 
factors, these differences resulted in different analytic approaches. 
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The addition of other substance use further complicates the difficulty of 
understanding the role of risky behaviors. As McCauley et al., highlighted, delinquency 
and risky behaviors may be linked, despite often being measured separately.15 Other 
substance use was one of the most discussed risk factors for NMUPD and may also be 
understood as delinquent behavior, given use of these substances is both illicit and risky. 
The shared risk factors associated with delinquency, other illicit substance use, and 
NMUPD need to be further distinguished to continue to understand the complex 
interactions. 
Mental health was associated with NMUPD in studies that used composite variables and 
specific drugs.15,16,19,21,29 The findings presented in this review suggest mental health may 
impact NMUPD differently by drug class and gender.15,27 Mental health was defined by 
past MDE, mental health treatment service utilization, and survey questions addressing 
feelings of sadness of hopelessness. These indicators are not diagnostic, and future work 
would benefit from exploring the relationship between mental health and NMUPD more 
thoroughly. As one study in this review demonstrated, the relationship between NMUPD 
and mental health may vary with symptom severity, which will have important 
implications.29 Five studies examined traumatic and adverse experiences, each finding 
significant relationships with NMUPD.15,30-32,42 These findings again demonstrate the 
interacting factors that contribute to NMUPD. Findings differed by gender, types of 
experiences, and frequency. The measurement of ACEs, in particular, encapsulates a 
variety of other factors identified in this review. As such, the unique context of the 
individual adolescent remains important, given that a number of identified factors interact 
with each other and influence health behaviors like NMUPD. Surprisingly, physical 
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health was not thoroughly discussed in the articles of this review. Physical health can 
vary in ways that impact mental health and every other factor discussed in this review. It 
will be beneficial to include variables related to physical health to better understand the 
relationship between health and NMUPD. 
Limitations 
Despite the evidence presented and discussed there are many limitations to the articles 
comprising this review. The literature in this review is based predominantly on cross-
sectional studies. Therefore, associations between NMUPD and covariates of interest 
cannot be interpreted as causal and temporal relationships cannot be established. This 
review is further limited by the number of secondary analyses. Research conducted in 
these analyses were restricted to the variables of interest and participant response choices 
provided by the parent studies. This prevented the addition of tools such as validated 
surveys or diagnostic criteria from being included in research. More problematic may be 
the operational definitions inherited from previous studies. NSDUH defines NMUPD as 
“use in any way not directed by a doctor, including use without a prescription of one’s 
own; use in greater amounts, more often, or longer than told to take a drug; or use in any 
other way not directed by doctor”.1 This definition dominates the literature; however, it 
may be too broad to provide a more detailed understanding of NMUPD in adolescents. 
This definition does not provide an opportunity to further navigate motivations for 
engaging in NMUPD and may preclude assessing methods of attainment. For example, 
an adolescent may take a higher dose than prescribed as a means of self-medication 
which is distinctly different than an adolescent taking a medication not as prescribed for 
the experience of getting high. There are clinical and preventative implications in this 
distinction. Similarly, use was often defined in terms of the last month or past year. 
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Therefore, much of the research is not able to characterize NMUPD by pattern of use. 
This too, may impact how to best address the needs of adolescents who are using 
prescriptions non-medically. Many of the articles in this review utilized composite 
variables, particularly regarding drug classes, which inhibited more thorough 
examination of risk factors by drug class. This may be due to low base rates of outcomes 
of interest. While combining drug classes can increase power, research focused on 
specific drug classes will better facilitate more targeted approaches to handling NMUPD. 
Further, each study in this review relied on participant self-reporting of drug use, which is 
likely to result in reporting bias. Future research on adolescent NMUPD can learn from 
these limitations to continue building knowledge related to this phenomenon.  
Future Directions 
Future work should use different methodologies to move from descriptive approaches to 
the more analytic approaches needed to understand the mechanisms driving associations 
between demographic, social, and health related factors associated with the development 
of adolescent NMUPD. Variables of interest should be assessed using standardized and 
validated tools, to provide consistency and promote comparison between individuals and 
groups across studies. The complex, conflicting findings presented in this review suggest 
that risk factors are not well understood at the aggregate levels provided. However, they 
also demonstrate the importance of the individual context in understanding NMUPD in 
adolescents. The future of this line of inquiry will benefit from more individual and 
population specific research (e.g. geography, social environments) in conjunction with 
consistent measurement. The utilization of standardized tools and more context centered 
approaches will better address the needs of local populations. Longitudinal cohort studies 
are needed to assess exposure more accurately and to better account for time and the 
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development of NMUPD. Finally, more research should consider focusing on specific 
drug classes instead of a composite NMUPD variable, as evidence suggests risk factors 
vary by drug. This is particularly important as increased focus is dedicated to the nation’s 
opioid consumption. This review shows that factors influencing the non-medical use of 
prescription medications can vary by drug, but opioid specific findings are sparse. There 
is an abundance of literature addressing the opioid use and overdose crises related to 
adults, but it is now well established that experiences in adolescence impact outcomes in 
adulthood. Unfortunately, it appears using a composite variable to measure non-medical 
use of prescription drugs in adolescence was the norm for decades while using drug 
specific variables is more common in recent literature. This more specific work is 
necessary to address opioid misuse both now and in the future. The factors identified in 
this review warrant further exploration as they relate to opioids. Further, little research 
has thoroughly addressed how and when adolescents are exposed to opioids. It is 
established that sources of prescriptions drugs include family, peers, and health care. It is 
now time to bridge the gap between sources of opioids and the factors that influence their 
use by individuals and communities. 
Conclusion 
This review discussed several risk factors associated with adolescent NMUPD as 
identified through a systematic literature review. Race and gender were common 
variables associated with NMUPD, however, as discussed, these categories are likely 
proxies for other influential factors. Other demographic factors in this review, 
specifically geography and age, were considered to be significant in an adolescents’ 
NMUPD risk. Social influences remain of considerable interest in the NMUPD literature, 
specifically the role of parent and peers. Mental health factors like MDE and violence 
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were also associated with increased risk. Current knowledge should be leveraged to 
continue addressing the limitations of the studies included in this review and advance 



























Table 2.1 Drug Categories  
Drug category Example Short term effects 
Opioids 
Includes Vicodin®, Oxycontin®, 
Percocet®. 




Includes Ritalin®, Adderall®, 
Dexedrine®. 





Includes several depressants such 
as benzodiazepines and anxiolytics 
like Xanax® and Klonopin®.  
Also, closely associated with 
tranquilizers, which have similar 
effects and can include 
antipsychotics like Seroquel® and 
Risperdal®. 
 
Drowsiness, dizziness, slowed 




















Table 2.2 Parent Studies 
Parent study Description 
California Healthy Kids Survey (CHKS) 
Created by the California Department of Education and 
administered to grades 5 and above. The goal is to 
provide data to be used for the improvement of student 
performance and health. 
Minnesota Study Survey (MSS) 
 Administered to students in grades 5,8,9, and 11 every 
three years. The survey asks students about their health, 
climate, activities, behaviors, and more. 
Monitoring the Future (MTF) 
The MTF surveys approximately 50,000 8th,10th, and 
12th grade students annually. Initiated in 1975, this study 
provides information on attitudes, beliefs, and behaviors 
of youth in the United States. 
National Survey Adolescents-
Replication (NSA-R) 
A nationally representative study which aimed to 
identify the prevalence of mental health disorders 
associated with exposure to traumatic events and to 
examine the risk factors associated with mental health 
outcomes. 
The National Monitoring of Adolescent 
Prescription Stimulants Study (N-
MAPSS) 
A cross-sectional study of adolescents ages 10-18 
recruited from urban, suburban, and rural zip codes of 
10 US cities. Aimed to assess medical use and 
nonmedical use of stimulants, opioids, and other 
prescription medications. 
National Survey of Drug Use and Health 
(NSDUH) 
Sponsored by the Substance Abuse and Mental Health 
Service Administration (SAMHSA), the NSDUH has 
provided nationally representative samples of 
approximately 70,000 participants annually since 1971. 
Respondents ages 12 and older provide information on 
alcohol and tobacco use, illicit drug use (including 
NMUPD), and mental health. 
Secondary Study Life Study (SLSS) 
Sampled 7th-12th grade students from five Michigan 
schools. Collected data on classes of abused 
medications, nonmedical use, and medical misuse. 
Youth Risk Behavior Surveillance 
System (YRBSS) 
A nationally representative survey administered every 
two years to high school students since 1991. The 
YRBSS was developed to monitor behaviors 
contributing to health outcomes, particularly those 
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Chapter 3  
Opioid Prescribing to Adolescents upon Discharge  
from an Admission of 48 hours or Less1 
Abstract 
The purpose of this study was to examine prescribing patterns and identify characteristics 
associated with an adolescent being prescribed an opioid at time of discharge from a 
hospital stay of 48 hours or less. We performed a retrospective cross-sectional analysis of 
EHR data from a pediatric health system. Our sample include 2,180 patient visits of 
which 35% received a prescription for an opioid medication upon discharge. We found 
both patient and clinical factors such as age, insurance status, pain scores, and unit of 
discharge to be significantly associated with increased odds of receiving an opioid upon 
discharge. This work contributes to understanding how an adolescent population is 
exposed to opioids through the healthcare system. Characterizing opioids prescribed upon 
discharge is one step towards a better understanding of how opioids enter communities 







1 This chapter is the author’s original work. A final version of this manuscript is published as Axson, S. A., Giordano, N. A., McDonald, 
C. C., & Pinto-Martin, J. A. (2019). Opioid Prescribing to Adolescents upon Discharge from an Admission of 48 Hours or Less. Journal 
of Child & Adolescent Substance Abuse, 28(3), 190-199. doi:10.1080/1067828X.2019.1679688. No modifications are permitted without 




Adverse health outcomes related to the nation’s opioid consumption, including overdose 
deaths, addiction, and emergency room visits, continue to rise in all 50 states (Kolodny et 
al., 2015; Rudd, 2016; Rudd, Aleshire, Zibbell, & Gladden 2016; Seth, Scholl, Rudd, & 
Bacon, 2018). According to the Centers for Disease Control and Prevention (CDC) the 
current opioid epidemic is a top public health priority (CDC, 2017; Kolodny et al, 2015). 
While adults over 18 years of age represent the largest population driving these 
outcomes, young people are also at risk to experience negative outcomes related to 
opioids (Allen et al., 2017). Adolescence is a period marked by rapid growth, 
development, and emerging independence; exposure to opioids during this period, 
whether by medical or non-medical means, can have long-lasting consequences. 
Evidence suggests that receiving an opioid prescription is correlated with future opioid 
misuse (McCabe et al., 2017; Miech, Johnston, O’Malley, Keyes, & Heard, 2015). Miech 
et al. (2015) found that receiving an opioid prescription before high school graduation 
increased the odds of misuse up to 33% by the age of 23, compared to those never 
receiving an opioid prescription. However, it is worth noting adolescents may also 
receive opioid medications through non-medical sources, as peers are another common 
source of opioids (Boyd, McCabe, Cranford, & Young, 2007; McCabe & Boyd, 2005). 
Nearly 25% of American high school seniors report lifetime exposure to medical or non-
medical (i.e. access from peers or family members) prescription opioids (McCabe, West, 
Teter, & Boyd, 2012). 
Health care professionals are charged with effectively managing patients who need 
opioids in the context of adverse public health outcomes. Continued efforts to develop 
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and promote safe prescribing requires understanding of current prescribing practices. 
Prescribing practices related to opioid medications have changed over time, and 
variations by specialty, procedure, and patient populations exist (Barnett, Olenski, & 
Jena, 2017; Fortuna, Robbins, Caiola, Joynt, & Halterman; Guy et al., 2017; Hill, 
McMahon Stucke, & Barth, 2017; Levy, Paulozzi, Mack, & Jones, 2015; McCabe et al., 
2017; Volkow, McLellan, Cotto, Karithanom, & Weiss, 2009). However, much of the 
research focuses on the adult population. Some research suggests similar variation in 
younger populations. A five-year retrospective study in children with sickle cell disease, 
a widely researched condition with recognized pain protocols, showed marked variation 
in opioid prescriptions following a pain crisis (Levy, Paulozzi, Mack, & Jones, 2015). 
Other analyses showed geographical variations in medical and non-medical adolescent 
opioid use and differences in pediatric opioid consumption during hospitalization by race 
(McCabe, West, Veliz, McCabe, Stoddard, & Boyd, 2017; Kozlowski et al., 2014).  
Overall, much less is known about opioid prescribing patterns among adolescent 
patients and how these prescribing patterns relate to the clinical and demographic 
characteristics of the patient.  Further characterizing when and why adolescents are 
prescribed opioids will contribute to a better understanding of opioid exposure in this 
population, and can contribute to future efforts promoting safe use. Data on how 
adolescents are prescribed opioids in acute care settings are a useful first step to 
understanding the relationship between providers’ prescribing practices and adolescent 
use. The purpose of this analysis was to examine current prescribing patterns in a 
comprehensive pediatric health care system and identify characteristics associated with 
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an adolescent being prescribed an opioid at time of discharge from a hospital stay of 48 
hours or less.  
Methods  
Data Acquisition and Participants 
This study was a retrospective cross-sectional analysis of adolescent patient data from the 
electronic health record (EHR) at a large urban northeastern pediatric health system. 
Patients were selected using the following inclusion criteria: ages 10 to 19; discharged 
with a pain medication from the emergency department (ED), an urgent care center, or 
from a hospital admission of 48 hours or less. To ensure a sample containing only unique 
patient visits, readmissions were not included. This time frame, in addition to allowing 
for particular focus on acute visits, is supported by research demonstrating a median stay 
of 2 days for pediatric visits not resulting in readmissions (Heslin, Owens, Simpson, 
Guevara, & McCormick, 2018). As there are specific clinical protocols and guidelines 
relating to the management of chronic pain, acute and chronic treatments may differ and 
therefore the decision was made to first examine acute visits. Prescription of non-opioid 
pain medications (e.g. NSAIDs) was chosen as the comparator group because of their 
similar indications for treating pain which has been shown to minimize the potential for 
unmeasured confounding in adult populations (Seamans et al., 2018). A random sample 
of 10% of the eligible patients from the EHR between January 2015 and January 2017 
was obtained for analysis resulting in a final analytic sample of 2,180 adolescents. This 
project was approved by the University of Pennsylvania Institutional Review Board. 
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Study Variables  
The primary outcome of interest, receipt of an opioid prescription at discharge, was 
dichotomized based on receipt of one of the following: hydrocodone, oxycodone, 
Tylenol® with codeine, Percocet®, Vicodin®. Covariates of interest included: age, sex, 
race, insurance status, surgery, health care practitioner prescriber, care unit from which 
patients were discharged, pain scores, and mental health diagnosis. Race was categorized 
as White, Black, and Other. Insurance status included both Medicaid and/or self-pay, and 
private insurance. Health care practitioner prescribers included physicians (MD/DO) and 
other prescribers (e.g. physicians’ assistants [PA]), and nurse practitioners [NPs]). This 
variable was made dichotomous as nurse practitioners and other providers (i.e. NP vs 
MDs, PAs). For the purpose of this analysis, care units from which patients were 
discharged were categorized into four groups: medical; surgical and intensive care units 
(ICU); urgent care and ED; and post-anesthesia care units (PACU). Pain scores included 
last recorded pain score before discharge, maximum pain score during stay, median pain 
score, and average pain score. Each pain score was based on a number rating scale 
ranging from 0 (no pain) to 10 (worst pain imaginable) obtained from the EHR. The 
surgery variable captures whether a patient underwent a surgical procedure during their 
visit, and was examined as a dichotomous variable. Mental health diagnosis was 
dichotomized based on if a patient had any active mental health diagnoses in the EHR at 
time of discharge. Information regarding smoking status, alcohol use, and substance use 





First, categorical and dichotomous variables were examined as frequencies and 
percentages; continuous variables were examined using measures of central tendencies 
(e.g. medians, interquartile range [IQR]). Comparative statistics (e.g. chi-square, Mann-
Whitney U) evaluated differences between demographic and clinical characteristics 
between individuals who did or did not receive an opioid. Bivariate logistic regressions 
were calculated to assess the association between demographic and clinical variables, and 
receipt of an opioid prescription upon discharge. Finally, a stepwise multivariate logistic 
regression was used to model the relationship between the significant variables from the 
bivariate regression and the outcome of interest. Variables with high collinearity were 
excluded. These variables included pain score measures (e.g. max pain score during stay, 
median pain score, and average pain score). Due to the nature of the relatedness of each 
pain measure, the regression process was completed with each pain variable as a 
predictor. Considering the complex and multidimensional nature of pain, we chose to 
consider a variety of pain measures before identifying which would help characterize 
prescribing practices. No significant differences were found based on the different pain 
variables and therefore last pain score before discharge was selected to be included. 
Models were compared using Akaike information criterion (AIC). Final variables 
included in the model were determined to be of best fit based on a variance inflation 
factors (VIF) of less than 10 and a Hosmer–Lemeshow test. All analyses were conducted 






The sample’s clinical and demographic characteristics are presented in Table 3.1. The 
sample was evenly split in regard to sex (47% male, 53% female) and insurance status 
(53.9% Medicaid/self-pay, 46.1% private) and was majority non-white (59%). The 
majority of the sample (51.6%) was discharged from the ED or an urgent care center 
while 22.3% were discharged from a surgical floor or an ICU, 19% from a PACU, and 
7% from a medical unit. Less than half of the sample (43%) underwent a surgical 
procedure during their admission and approximately a third of all patients were 
discharged with an opioid prescription (35.50%).  
Patient Sociodemographic Characteristics 
Bivariate logistic regression models were used to analyze the association between 
demographic and clinical variables and receipt of an opioid prescription at discharge 
(Table 3.2). Age was found to be a statistically significant predictor: older adolescent 
patients were more likely to receive an opioid prescription, with each year beyond 10 
years associated with a 9% increase (Odds Ratio [OR]=1.09; 95% Confidence Interval 
[CI]: 1.06-1.13; p<0.001). Individuals classified as Black or Other race were found to be 
significantly less likely to receive an opioid compared to White individuals (OR=0.18; 
95% CI: 0.14-0.24; p<0.001; OR=0.67; 95% CI: 0.51-0.88; p=0.004, respectively). 
Individuals with Medicaid coverage or self-pay were significantly less likely to receive 
an opioid at discharge than those with private insurance (OR=0.27; 95% CI: 0.23-0.33; 





Having a surgical procedure was also associated with increased odds of receiving an 
opioid (OR: 27.05; 95% CI: 21.26-34.72; p<0.0001). More frequent pain observations 
while in hospital were associated with increased odds ratios for receiving an opioid (OR: 
1.40; 95% CI: 1.35-1.44; p<0.0001). Increasing average, max, median pain, and last 
recorded pain measure score were found to be significantly associated with a lower 
likelihood of receiving an opioid prescription at discharge (p<0.01). For example, each 
one-point increase in an individual’s last pain assessment on a scale of 0-10, was 
associated with an unexpected 22% decrease in the odds of receiving an opioid (OR: 
0.78; 95% CI: 0.76-0.81; p<0.0001). Individuals who endorsed smoking had significantly 
increased odds of receiving an opioid, however much of these data were missing. There 
was no statistical difference in the odds of prescribing an opioid by mental health 
diagnosis, alcohol use, or substance abuse. 
Provider Characteristics 
The unit from which patients were discharged was significantly associated with an opioid 
prescription upon discharge. For example, individuals discharged from surgical or ICU 
units and PACUs were most likely to receive an opioid compared to patients discharged 
from the medical care units (OR=5.12; 95% CI: 3.49-7.58; p<0.0001; OR=4.68; 95% CI: 
3.17-6.96; p<0.0001, respectively). Alternatively, individuals discharged from the ED 
and urgent care settings were less likely to receive an opioid (OR=0.09; 95% CI: 0.06-
0.13; p<0.0001). There was no statistical difference in the odds of prescribing an opioid 
by health care provider’s licensure. 
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Multivariate Logistic Regression 
The multivariate logistic regression model produced from the stepwise process included 
the statistically significant variables from the bivariate analysis: age, race, surgery, 
insurance status, last pain score prior to discharge, and care unit. The final model 
estimates were found to fit the data appropriately (Hosmer-Lemeshow test, χ2=6.39, df=8, 
p=0.603). In the multivariate model, an increase in every year of age was found to be 
associated with a 14% increase in likelihood of receiving an opioid prescription 
(Adjusted Odds Ratio [AOR]= 1.14; 95% CI: 1.08-1.20; p<0.0001). Race was not 
statistically significantly associated with receipt of an opioid. Individuals who had 
surgery were nearly twice as likely to receive an opioid compared to individuals who did 
not (AOR= 1.91; 95% CI: 1.17-3.10; p=0.01). Individuals with Medicaid coverage or 
who self-pay were 34% less likely to be prescribed an opioid at discharge compared to 
those with private insurance (AOR= 0.66; 95% CI: 0.50-0.87; p=0.004). Each 1-point 
increase in last documented pain assessment score prior to discharge was associated with 
a 15% increase in the likelihood of being prescribed an opioid (AOR= 1.15; 95% CI: 
1.08-1.22; p<0.0001). Compared to a medical unit setting as the referent group, 
individuals discharged from surgical units had the greatest odds of receiving an opioid 
(AOR= 4.84; 95% CI 3.14, 7.53; p<0.0001) followed by those discharged from the 
PACU (AOR= 4.27; 95% CI 2.70-6.81; p<0.0001). Individuals discharged from the ED 
and urgent care centers had statistically significantly lower odds of being prescribed an 
opioid (AOR= 0.09; 95% CI: 0.05-0.16; p<0.0001). These results can be found in Table 
3.2. Interaction terms between factors included in the final model were not statistically 
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significantly associated with opioid prescribing at discharge and did not improve model 
fit.  
Discussion 
Our findings indicate that for adolescents in a large urban pediatric health system, receipt 
of an opioid prescription upon discharge after an admission of less than 48 hours is 
associated with a combination of factors including clinical and sociodemographic 
characteristics. As earlier research has indicated, we identified that there was an increase 
in the likelihood of receiving an opioid prescription at discharge associated with each 
year of increasing age (Banerjee, Roland, Willke, Markdekian, & Garrison, 2017). In our 
sample, each year of increased age is associated with a 9% increase in the likelihood of 
being prescribed an opioid upon discharge. This information is clinically useful for 
providers who want to target efforts towards safe opioid use and disposal. Other research 
has demonstrated younger patients are more likely to receive an opioid prescription for 
longer than five days (DePhillips, Watts, Lowry, & Dowd, 2017). However, the 
comparison was across age groups receiving an opioid, and did not include those who did 
not receive an opioid (Dephillips, Watts, Lowry, & Dowd, 2017). Study findings 
regarding the role of sex in opioid prescribing are mixed and do not show a consistent 
relationship between sex and opioid use (McCabe et al., 2017; McCabe, West, & Boyd, 
2013; Groenewald, Rabbitts, Gerbert, & Palermo, 2016;). We did not find a significant 
difference in receiving an opioid prescription between male and female adolescents.  
While race was significant in the bivariate analysis, it was not significant in the 
multivariate model, which is contrary to some previous research findings (McCabe et al., 
2017; Fortuna et al., 2010; Groenewald et al., 2018). Kozlowski et al. (2014) reported 
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that white pediatric patients consume more opioids throughout hospitalization compared 
to non-white patients, and Groenewald et al. (2018) found white pediatric patients were 
more likely to receive an opioid during outpatient visits in a nationally representative 
sample (Groenewald et al., Kozlowski, Kost-Byerly, & Colantuoni, 2014). However, our 
study uniquely examined prescribing to adolescents at time of discharge. The lack of a 
significant association with race likely reflects the many factors that contribute to 
prescribing. While this paper begins to address some of these factors such as insurance 
and discharge unit, other important factors including diagnosis, specific procedure, and 
in-hospital pain management protocols were unavailable for this analysis.  Insurance 
status remained statistically significant, with those with Medicaid coverage and those 
who self-pay having lower odds of receiving an opioid prescription, which may reflect 
confounding between race and insurance status. In addition, there is a marked difference 
in the insurance status of the patient populations treated in the four clinical settings in our 
sample. Over half (51.60%) of the overall sample, and 70% of patients with Medicaid or 
who self-pay, were discharged from the ED or an urgent care center. ED and urgent care 
centers treat a wide variety of conditions such as fever and otitis media that do not require 
transfer to a higher acuity floor but may still warrant dispensing a non-opioid pain 
medication (Mehrotra, Wang, Lave, Adams, & McGlynn, 2008). This may contribute to 
the lower odds of receiving an opioid associated with the ED or urgent care centers. 
Other studies support the possibility that Medicaid and other sociodemographic 
characteristics are associated with increased ED utilization (Alpern et al., 2014; Fishman, 
McLafferty, & Galanter, 2018; Miller-Matero, Coleman, Aragon, & Yanez, 2018; 
Montalbano, Rodean, Kangas, Lee, & Hall, 2016; Phelps et al., 2000; Tang, Stein, Hsia, 
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Maselli, & Gonzales). However, further investigation of these factors and their influence 
on opioid prescribing is beyond the scope of this study and would necessitate gathering 
data on variables such as access to primary care and other resources. 
We found no difference between NPs and other prescribers in likelihood of 
prescribing opioids at discharge, but we did find significant differences based on the type 
of unit from which patients were discharged. This is consistent with other studies 
showing variation in opioid prescribing is often related to medical specialty, setting, and 
patient condition (Barnett, Olenski, & Jena, 2017; Fortuna et al., 2010; Guy et al., 2015; 
Hill et al., 2017; Levy et al., 2015; Heslin et al., 2018; Volkow et al., 2011). Discharge 
from an ICU, PACU, or Medical Unit were associated with higher odds of an opioid 
prescription upon discharge. This is likely due, in part, to the severity of clinical 
characteristics associated with conditions which required admission to a floor compared 
to conditions treated in the ED or an urgent care center without transfer to another unit. 
The ED and urgent care centers were associated with significantly lower odds of 
receiving an opioid prescription. This is consistent with the literature demonstrating EDs 
are not frequent sources of opioid prescriptions upon discharge (Levy et al., 2015; 
Menchine, Axeen, Plantmason, & Seabury, 2014; Niska, Bhuiya, & Xu, 2010). This may 
be due to the variety of conditions treated in these settings as well as the growing 
attention and concern around opioid prescribing. Our finding of increased odds of opioid 
prescription associated with having surgery is also supported by previous research 
(Chung et al., 2018). These statistically significant findings can be of use to clinical 
leadership investing resources towards patient education interventions.  
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Contrary to the bivariate analysis, the relationship between pain and opioid 
prescribing was as expected in the adjusted multivariate analysis, with higher pain scores 
associated with higher odds of receiving an opioid prescription. This flip is possibly an 
example of Simpson's paradox; therefore, the adjusted odds ratio indicates the value of 
accounting for other covariates (Pourhoseingholi, Baghestani, & Vahedi, 2012). Monitto 
et al. (2017) did not find a significant relationship between pain score and opioid 
prescription in a multivariate model, but did find higher pain scores to be associated with 
increased opioid consumption in a pediatric population (Monitto et al., 2017). Pain is 
multidimensional and the relationship between pain scores and opioid prescribing in this 
population warrants further exploration. This study does not account for pain medication 
administered before discharge and could benefit from more detailed information about 
patient diagnoses and procedures. It is possible this information will allow for clearer 
findings in future work. Regardless of these shortcomings, this work underscores that 
regular pain assessments inform pain management and can contribute to addressing 
patient needs during their stay and upon discharge. Appropriately managing pain has 
important clinical and public health education as other research has demonstrated opioids 
prescribed to the adolescent and pediatric population often go unused and are not 
properly disposed (Groenewald, 2019). 
Smoking, alcohol use, and substance use had a large degree of missing data and 
therefore were not included in the multivariate analysis. We highlight these findings so as 
to underscore the need for consistent and transparent documentation of risk factors 
associated with potential misuse. These variables would be useful to have in the future in 
the context of the ongoing opioid crisis and the promotion of safe prescribing and use. A 
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large body of evidence demonstrates significant associations between the use of other 
substances and the misuse of prescription opioids (McCabe et al., 2012; Nakawaki & 
Crano, 2012; Schepis & Krishnan-Sarin, 2008; Wu, Pilowsky, Patkar, 2008). EHR data 
does not capture all of the information exchanged between a provider and a patient, and 
the degree to which these data are missing does not necessarily mean that conversations 
of substance use are not happening. However, information regarding patient substance 
use can help providers promote appropriate prescription opioid use.  
It is important to note the limitations of this work. This was a cross-sectional study 
and therefore associations cannot be interpreted as causal. Additionally, while the 
outcome of interest was receipt of an opioid prescription, we do not have data on dosage 
prescribed, if the opioid prescriptions were filled, and how they were used by the patient. 
However, our clinical findings can potentially inform interventions for adolescents in the 
acute care setting both in terms of location and clinical characteristics. Our sample was 
hospital based from one pediatric health system and comprised only of adolescents who 
received a pain medication prescription upon discharge. Therefore, results may not be 
generalizable to other patient populations. In addition, there may be inherent clustering 
by prescribing providers within units in this sample. Though specific providers were not 
accounted for, the modeling sought to address both unit type and prescriber license. 
Compared to other pediatric investigations that include infants, our study focuses on 
opioid exposures to a particularly at-risk population where effective preventive strategies 
capable of mitigating the incidence of opioid initiation and misuse are urgently needed: 
adolescents. Unique from other observational pediatric cohort studies, our investigation 
includes a comparable control group of patients still requiring pain medication at time of 
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discharge, yet left without an opioid. Finally, EHR data provides a limited view of the 
both the clinical environment and the social environment from which these patients 
come. Despite the limitations of this study, to date it is the first of our knowledge to 
consider acute care opioid prescribing practices among adolescents following short-term 
hospitalization. As such, it offers a new perspective to better understanding opioid 
exposure to a vulnerable population in the midst of a national public health crisis. 
Conclusion 
Among a sample of adolescent patients discharged with a pain medication (opioid and/or 
non-opioid) after a hospital admission of 48 hours or less, this study identified important 
clinical and patient characteristics associated with receipt of an opioid prescription at 
discharge. Specifically, increased age, elevated pain score prior to discharge, having 
private insurance, and being discharged from an inpatient care unit compared to an ED or 
urgent care setting are significantly associated with an adolescent being prescribed an 
opioid at discharge. Because efforts to promote safe opioid use in adolescents requires an 
understanding of the current context of prescribing, these findings can be used to inform 
clinical practice and further research. These findings highlight the multifactorial nature of 
opioid prescribing to adolescents and the ongoing need to better characterize the use of 
opioids in the adolescent population. Future work should aim to include additional 
variables that were not available for this study, such as substance use and social factors. 
Future findings related to the adolescent population can continue to inform the 





Table 3.1 Demographics 
 
Table 1: Demographics 
 Overall Sample No Opioid Prescribed Opioid Prescribed P 
 n % n % n %  
Total  2180  1406 64.5% 774 35.5%  
Sex        
Male  1024 47.0% 664 47.2% 360 46.5% 0.7833 
Female 1156 53.0% 742 52.8% 414 53.5%  
Race        
White 893 41.0% 414 29.4% 479 61.9% <0.001 
Other 281 12.9% 158 11.2% 123 15.9%  
Black 1006 46.1% 834 59.3% 172 22.2%  
Non-Opioid Prescribed        
Yes  1931 88.6% 1406 100.0% 525 67.8% <0.001 
Insurer        
Medicaid/Self-pay  1176 53.9% 607 43.2% 569 73.5% <0.001 
Private 1004 46.1% 799 56.8% 205 26.5%  
Surgery        
Yes 937 43.0% 268 19.1% 669 86.4% <0.001 
Prescriber        
Physician & Other Providers 1631 74.8% 1038 73.8% 593 74.8% 0.166 
Nurse Practitioner  549 25.2% 368 26.2% 181 25.2%  
Smoking Status         
Never 740 33.9% 529 37.6% 211 27.3% <0.001 
Yes 151 6.9% 115 8.2% 36 4.7%  
Not Asked 1289 59.1% 762 54.2% 527 68.1%  
Alcohol Use         
Never 44 2.0% 27 1.9% 17 2.2% 0.497 
Yes 5 0.2% 2 0.1% 3 0.4%  
Not Asked 2131 97.8% 1377 97.9% 754 97.4%  
Substance Abuse         
No 43 2.0% 25 1.8% 18 2.3% 0.477 
Yes 6 0.3% 3 0.2% 3 0.4%  
Not Asked 2131 97.8% 1378 98.0% 753 97.3%  
Mental Health Diagnosis         
Yes 232 10.6% 147 10.5% 85 11.0% 0.757 
Care Unit Discharged From        
Medical 154 7.1% 98 7.0% 56 7.2% <0.001 
Surgical/ICU 487 22.3% 124 8.8% 363 46.9%  
Urgent Care/ED 1124 51.6% 1071 76.2% 53 6.8%  
PACU 415 19.0% 113 8.0% 302 39.0%  
Years of Age, M (IQR) 14.2 (12.0, 16.4) 14.0 (11.0, 16.2) 14.8 (12.5, 16.8) <0.001 
Max Pain, M (IQR) 6.0 (4.0, 8.0) 7.0 (4.0, 8.0) 6.0 (3.0, 8.0) <0.001 
Average Pain, M (IQR) 4.0 (1.5, 6.6) 5.3 (2.5, 7.0) 2.3 (0.8, 4.0) <0.001 
Median Pain, M (IQR)  4.0 (0.0, 7.0) 5.5 (2.0, 7.0) 2.0 (0.0, 4.0) <0.001 
Pain Assessments During 
Hospitalization, M (IQR) 
3.0 (1.0, 6.0) 2.0 (1.0, 3.0) 7.0 (4.0, 11.0) <0.001 
Pain Score Prior to 
Discharge, M (IQR) 
3.0 (0.0, 6.0) 5.0 (1.0, 7.0) 2.0 (0.0, 4.0) <0.001 
Abbreviations: ICU, intensive care unit; ED, emergency department; PACU, post-anesthesia care unit. M, Median; IQR, 
interquartile range. 
Test of differences in proportions between opioid prescribing using chi-square, and fisher’s exact when cell count <10. 
















Table 2: Logistic Regression Derived Odds Ratio of Being Prescribed an Opioid at Discharge 
  Unadjusted Model Multivariate Model 
  OR (95% CI) P AOR (95% CI) P 
Age  1.09 (1.06 - 1.13) <.0001 1.14 (1.08 - 1.20) <0.0001 
Surgical Status        
No Surgery  Ref       
Yes Surgery  27.05 (21.26 - 34.72) <.0001 1.91 (1.16 - 3.11) 0.010 
Prescriber        
Physician & Other Providers  Ref       
Nurse Practitioner   0.86 (0.70 - 1.06) 0.151    
Race        
White  Ref       
Black  0.18 (0.14 - 0.22) <.0001 0.95 (0.68 - 1.34) 0.780 
Other  0.67 (0.51 - 0.88) 0.004 0.99 (0.69 - 1.44) 0.976 
Sex        
Female  Ref       
Male  1.03 (0.86 - 1.23) 0.749    
Insurance Status        
Private  Ref       
Medicaid and Self Pay  0.27 (0.23 - 0.33) <.0001 0.66 (0.50 - 0.87) 0.004 
Mental Health Diagnosis         
No Ref       
Yes  Ref 1.06 (0.79 - 1.40) 0.703    
Average Pain [0-10]  0.75 (0.72 - 0.78) <.0001    
Max Pain [0-10]  0.95 (0.92 - 0.98) <.0001    
Median Pain [0-10]  0.76 (0.74 - 0.79) <.0001    
Number of Pain Obs. [1-41]  1.40 (1.35 - 1.44) <.0001    
Last Pain Score Prior to Discharge  0.78 (0.76 - 0.81) <.0001 1.15 (1.08 - 1.22) <0.0001 
Care Unit Discharged From        
Medical Units Ref       
ED & Urgent Care   0.09 (0.06 - 0.13) <.0001 0.09 (0.05 - 0.16) <0.0001 
PACU Recovery Units  4.68 (3.17 - 6.96) <.0001 4.27 (2.70 - 6.81) <0.0001 
Surgical Units and ICUs  5.12 (3.49 - 7.58) <.0001 4.84 (3.14 - 7.53) <0.0001 
Smoker        
Not Asked Ref       
Yes  0.45 (0.30 - 0.66) <0.001    
No  0.58 (0.47 - 0.70) <0.001    
Alcohol Use        
Not Asked Ref       
Yes  2.38 (0.36 - 19.53) 0.368    
No  0.87 (0.48 - 1.64) 0.655    
Substance Abuse        
Not Asked Ref       
Yes  1.39 (0.23 - 8.28) 0.707    
No  0.76 (0.41 - 1.42) 0.377    
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Chapter 4  
Evaluating analgesics prescribed to adolescents upon hospital discharge: 
Findings from one pediatric hospital, 2015-2019 
Abstract 
The purpose of this study was to describe the opioid prescribing practices over time to 
adolescents upon discharge from one urban pediatric medical center in Pennsylvania. 
Using the electronic health record, a retrospective cross-sectional analysis of 9,176 
adolescents discharged after an admission of 5 days or less between January 2015 and 
December 2019 was performed. Four outcome groups, based on the analgesics prescribed 
at discharge, were created for a multivariable multinomial logistic regression: 1) 
discharged with no pain medication, 2) discharged with a non-opioid only, 3) discharged 
with an opioid only, 4) discharged with both an opioid and a non-opioid. Approximately 
30% of patients seen over this time period were discharged with an opioid. The odds of 
being discharged with only an opioid decreased each year (Adjusted Odds Ratio 
[AOR]=0.79, CI:0.66-0.94), while odds of being discharged with only a non-opioid 
increased each year (AOR= 1.34, CI: 1.23-1.46). Additionally, these results accounted for 
exposure to Pennsylvania’s Safe Prescribing of Opioids for Pediatric and Adolescent 
Populations guidelines. Following implementation of these guidelines, the odds of being 
discharged with both an opioid and a non-opioid decreased (AOR= 0.59, CI: 0.42-0.84), 
but there were no statistically significant changes related to discharges with an opioid 
only or a non-opioid only. Considering the significant trend identified by year, it is likely 
the safe prescribing guidelines reflect current practice. This work contributes to an 
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understanding of opioid prescribing trends in the adolescent population and is 




As the nation’s opioid use continues to be a topic of national attention, prescription 
opioids remain valuable analgesics for many populations, including young patients. 
While opioid prescribing has generally declined on the national level since its peak in 
2010, practice continues to evolve and variation exists.1 A number of notable bodies, like 
the Centers for Disease Control (CDC), the American Pain Society, and the American 
Academy of Pain Medicine, have created guidelines to help inform prescribing practices.2 
Though implementation of these guidelines is not mandatory for clinicians,  evidence 
suggests they have contributed to changes in prescribing practices. 
In 2016, the CDC released its Guideline for Prescribing Opioids for Chronic Pain. 
Even though use of opioids in the medical setting was already steadily declining for 
several years, the release of these guidelines was associated with an even faster rate of 
decline.3 Similar findings, focused on emergency care, have been reported regarding 
state-level efforts, including Ohio and Washington.4 Additionally, a study of two 
emergency departments in Philadelphia found sustained changes in opioid prescribing for 
dental, neck, back or unspecified chronic pain, illustrating significant impact at a local 
level.5 Many established guidelines and efforts to characterize opioid prescribing over 
time have focused on adult or pediatric patients with chronic pain.2,6-9 There remains a 
paucity of studies addressing use of opioids for non-chronic pain in adolescents, even 
though the majority of chronic opioid use begins with the treatment of non-chronic 
pain.8,9 
The National Academies of Science, Engineering, and Medicine have outlined the 
need for researchers to monitor the uptake and impact of clinical practice guidelines on 
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opioid prescribing for patients in acute pain, including children and adolescents.10 
Further, Pennsylvania issued its Safe Prescribing of Opioids in Pediatric and Adolescent 
Populations guidelines in 2017. This adolescent specific guideline, addressing pain 
assessment, indications for opioids, and prescribing, presents a valuable opportunity to 
further understand prescribing in this population.11 As such, the purpose of this study was 
to examine changes in opioid prescribing over time to adolescents upon discharge from 
acute care at one urban pediatric academic medical center in Pennsylvania. 
Methods 
Sample and Setting 
A retrospective review of a random sample of 10,000 patients admitted between January 
2015 and December 2019 was conducted. Adolescents between the ages of 10 and 19 
who were admitted to one academic pediatric hospital for 5 days or less were eligible. 
Each visit corresponded to a unique patient and readmissions were not included. If a 
patient had multiple visits during the study period, only the first visit was included. The 
final analytical sample comprised 9,176 adolescents. This study was approved by the 
Institutional Review Board at the University of Pennsylvania. 
Discharge Medication Group  
The aim of this analysis was to characterize prescribing practices to adolescents at time of 
discharge. Therefore, the final sample was organized into four independent and mutually 
exclusive groups based on the pain medications prescribed at discharge: 1) those 
discharged without pain medication; 2) those discharged with non-opioid pain medication 
only; 3) those discharge with an opioid medication only; and 4) those discharged with 
both an opioid and a non-opioid medication. The primary aim was to determine the 
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patient, clinical, and temporal factors that contributed to the likelihood of an adolescent 
being discharged from an inpatient unit into one of these groups. 
Discharge Medication Dosage 
The secondary outcome of interest was dosage of opioid prescribed at time of discharge. 
A sub-group analysis of individuals prescribed an opioid was conducted. Dosage 
information for each prescription opioid in the sample was obtained and converted to 
morphine milligram equivalents per day (MME/day) using the CDC’s guidelines for 
computing dosage. This conversion accounted for adolescents prescribed multiple 
medications and allowed for the comparison of dosages across different prescription 
opioids.12 
Temporal Factors 
Time was examined by year and relative to guideline implementation. Year of discharge 
was included as a continuous measure from 2015 to 2019 to determine if time influenced 
prescribing practices. Further, Pennsylvania issued its Safe Prescribing of Opioids in 
Pediatric and Adolescent Populations around the last quarter of 2017. Therefore, 
adolescents discharged after September 1st, 2017 were considered to be cared for in the 
“post-guideline” implementation period. Those discharged prior to this date were 
considered to be in the “pre-guideline” implementation period. Examining time as both a 
continuous variable (e.g. year) and as a dichotomous exposure variable representing (e.g. 
pre-and post-guidelines) allowed for an exploration of how the introduction of local 
guidelines may have influenced prescribing practices while accounting for temporal year 




Patient and clinical characteristics were obtained from the electronic health record (EHR) 
of one single academic hospital. Age, race, sex, length of stay (days), insurance provider, 
mental health diagnosis, surgical status, unit of discharge, administration of opioids 
during inpatient stay, and pain scores were extracted. Pain was measured by the numeric 
rating scale of 0 (no pain) to 10 (worst pain). Age, length of stay (LOS), and pain scores 
were kept as continuous variables. Race was characterized as White, Black, and other or 
unknown. Insurance provider was dichotomized as Medicaid/self-pay and private 
insurance. The units of discharge included medical units or intensive care units (ICU). 
Surgical flags and mental health flags were created to indicate whether a surgical 
procedure was performed during the admission and if there was an active mental health 
diagnosis, respectively. A dichotomous variable (e.g. yes/no) was created to indicate 
whether a patient received opioids as an inpatient.  
Statistical Analysis 
Descriptive and comparative statistics (e.g. ANOVA, chi-square, Kruskal-Wallis, Mann-
Whitney U test) were computed for each of the four medication outcome groups. Post 
hoc pairwise comparisons identified any statistically significant differences between the 
four groups across patient, clinical, and temporal factors. 
Multinomial Logistic Regression to Examine the Effect of Temporal Factors. To identify 
changes in the odds of being discharged with an opioid over time, a multivariable 
multinomial logistic regression model was constructed. First, single variable multinomial 
logistic regressions determined the associations between the patient, clinical, and 
temporal factors and the likelihood of being discharged into each prescription medication 
outcome group. Significant variables from the single multinomial logistic regression were 
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included in the final multivariable model. Including these patient- and clinical-factors in 
the regression model makes it possible to control the variance and in turn identify the 
effect of the temporal factors (year and guideline exposure) on discharge medication 
group outcomes. A backwards selection approach was used to determine the final model, 
and fit was assessed using AIC values. Significance was set at p < 0.01 and all analyses 
were conducted in SAS 9.4 (SAS Institute, Cary NC). 
Change in Opioid Dosage over Time. To determine changes in opioid dosage prescribed 
over time, a sub-group analysis was conducted with data from individuals discharged 
with any opioid. Differences in the distribution of MME/day per year were assessed using 
a Kruskal-Wallis test. Next, a Mann-Whitney U test was used to compare the 
distributions of MME/day prescribed to patients discharged with an opioid prescription 
prior to and after the release of guidelines (e.g. prior to and after September 2017).  
Results 
The final sample included 9,176 adolescents (Table 4.1). The sample was evenly split on 
gender and on discharge year. Nearly 65% had private insurance. The majority of the 
sample was White (57%), 28% of the sample was Black, and 15% was either another race 
or unknown. More than half the sample (52.5%) was discharged with no pain medication. 
Approximately one third (30.4%) of the sample left with an opioid. Of those who left 
with an opioid 11.5% left with only an opioid, while 88% left with prescriptions for both 
an opioid and a non-opioid pain medication. Less than 20% of the sample left with a 
prescription for only a non-opioid pain medication. Further, there was a temporal change 
in the proportion of adolescent patients discharged across medication groups year to year. 
Chi-square tests indicated significant differences in the proportion of patients in each 
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medication group over time. For example, 6% of those discharged in 2015 were in the 
opioid only group, compared to 2019, when less than 2% were discharged in the opioid 
only group (Figure 4.1). 
The discharge medication groups differed from each other across clinical- and 
demographic-factors (Table 4.1). Pairwise comparisons showed that these differences 
were mostly driven by the group which received no pain medication upon discharge and 
the groups that received any pain medication (Appendices A-F). For example, pairwise 
comparisons identified that the group that received both an opioid and non-opioid upon 
discharge significantly differed from the group that received no medication on every 
variable except age. Single variable multinomial regression further informed these 
findings and determined race, age, mental health, surgical status, receipt of inpatient 
opioid, LOS, guideline exposure, year, average pain, and insurance group were 
significantly associated with discharge medication group and therefore to be considered 
for full multivariable multinomial logistic regression (Appendix G). 
Temporal Factors  
In the final multivariable model (Table 4.2), each year was associated with 21% decrease 
(AOR=0.79, CI:0.66-0.94) in the odds of being discharged with only an opioid compared 
to no medication, and a 34% (AOR= 1.34, CI: 1.23-1.46) increase in leaving with a non-
opioid only. Adjusting for all other covariates, including year, being discharged after the 
release of the guidelines was associated with a 41% decrease (AOR= 0.59, CI: 0.42-0.84) 
in the likelihood of being discharged with both an opioid and non-opioid, but no 




Demographic Factors  
Compared to patients who are White, Black adolescents were significantly more likely to 
be discharged with both an opioid and a non-opioid (AOR= 1.31, CI: 1.04-1.64). There 
were no significant differences by race between the opioid only group and the non-opioid 
only group. Further, there were no significant associations by age or insurance provider 
(Table 4.2).  
Clinical Factors 
As expected, surgery was significantly associated with increased odds of being in any 
discharge medication group (both: AOR= 46.92, CI: 37.67-58.42; opioid only: AOR= 
7.73, CI: 5.75-10.38; non-opioid only: AOR= 4.53, CI: 3.84-5.36) as was receiving an 
opioid during the inpatient stay (both: AOR= 43.07, CI: 32.72-56.70; opioid only: AOR= 
31.10, CI: 19.72-49.05; non-opioid only: AOR= 1.94, CI: 1.65-2.27). Similarly, increased 
average pain scores were associated with increased odds of being in any medication 
group (both: AOR= 1.49, CI: 1.42-1.55; non-opioid: AOR= 1.37, CI: 1.33-1.42, opioid: 
AOR= 1.43, CI: 1.35-1.53). Having an active mental health was significantly associated 
with lower odds of being in any medication discharge groups (both: AOR= 0.44, CI: 
0.34-0.57; opioid only: AOR= 0.51, CI: 0.33-0.78; non-opioid only: AOR= 0.58, CI: 
0.49-0.69). Each additional day as an inpatient decreased the odds of being discharged 
with an opioid only (AOR= 0.83, CI: 0.73-0.93. Finally, being discharged from a medical 
floor, compared to an ICU, was associated with receiving both an opioid and a non-
opioid (AOR= 3.45, CI: 2.57-4.63) (Table 4.2). 
Changes in Opioid Dosage  
After identifying that the odds of being discharged with an opioid changed over time, a 
sub-analysis was conducted on the 2,787 patients who were discharged with an opioid to 
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examine change in prescribed dosage (Table 4.3). A Kruskal-Wallis test determined 
significant differences in the distribution of MME/day prescribed across years (p < 0.01). 
While the median dosage prescribed was the same for each observed year (45 MME/day), 
the distribution as captured by the interquartile range (IQR) widens. For example, the 
IQR in 2015 was 41.4 MME/day to 45 MME/day. However, the IQR in 2019 was 30 
MME/day to 45/MME day. A similar change in distribution was observed when 
comparing MME/day dosages in the pre-guideline period compared to the post guideline 
period. The IQR of the pre-guideline period was 35.1 MME/day to 45 MME/day 
compared to the post-guideline IQR of 30 MME/day to 45 MME/day. However, a Mann-
Whitney U test determined this change in dosage distribution not to be statistically 
significant (p = 0.025) based on the p-value set at p < 0.01. 
Additionally, a sensitivity analysis was conducted to explore if the differences 
observed in prescribing and dosage were driven by the effects of temporal factors, or 
were possibly artifacts of clinical changes, such as lower pain scores over time. A linear 
regression found that when adjusting for discharge medication group, there was no 
significant difference year to year in pain scores.  
Discussion 
This study identified a decline in opioid prescribing and an increase in the prescribing of 
non-opioid pain medication between the years 2015 and 2019. These effects were 
observed while adjusting for factors contributing to the likelihood of receiving an opioid 
(variables in the final model). These results are similar to national trends. According to 
the CDC, opioid prescribing has decreased since 2010 by a number of measures including 
dosage, duration, rates, and co-prescribing with other medications like 
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benzodiazepines.3,13 Prescribing to younger populations has been less-well characterized 
but historically appears to be more stable over time than prescribing to adults.14 This 
considered, there is evidence that opioid prescribing has also decreased in this population 
in recent years. A study of commercially insured patients 18 years or younger from all 50 
states found opioid prescribing in the group to be steadily declining since 2012.15 This 
finding is supported by another study from Monitoring the Future which determined 
medical use of opioids by adolescents peaked in 2002 and remained stable until declining 
in 2013.16 We also determined that dosage prescribed upon discharge decreased 
significantly from 2015 to 2019. Importantly, it is essential to consider patient outcomes 
when noting changes in prescribing practices. While our ability to explore those 
outcomes was limited in the scope of this study, we did find that average pain did not 
change significantly over time, indicating that decreased use of opioids did not come at 
the cost of pain management in this sample. 
While national trends suggest decreased prescribing over time, it is known that wide 
variations exist. For example, in 2015 the average amounts of opioids prescribed in the 
top quartile of counties was nearly six times the amounts prescribed in the lowest quartile 
of counties. A number of factors may contribute to this difference, such as the prevalence 
of painful conditions, access to healthcare, and population characteristics.1,13,17-22 
However, these factors do not fully explain wide variations and may suggest inconsistent 
practice and lack of consensus regarding use of opioids.13 As a result, efforts like the 
creation of guidelines continue to grow. Though not mandatory, guidelines can be 
attractive options to address specific health issues and patient populations.3,4  
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Many factors contribute to the impact of guidelines influencing practice, however, 
there are several successful examples related to opioid prescribing.3,23 Guidelines from 
the CDC, as well as more local efforts in emergency departments and surgical specialties 
have proven effective. However, there remains a need to engage in more focused efforts, 
particularly in pediatric and adolescent populations.24 In 2017, Pennsylvania promoted its 
Safe Prescribing of Opioids in Pediatric and Adolescent Populations guidelines. These 
guidelines reiterate that opioids should be reserved for the treatment of moderate to 
severe pain, starting with short-acting opioids and low dosing. The use of scheduled non-
opioid pain relievers is also recommended to help manage pain.11  
We found that, after controlling for all other variables, being discharged in the post-
guideline period was associated with lower odds of receiving both an opioid and a non-
opioid but was not significantly associated with lower odds of being discharged with only 
an opioid or non-opioid medication. This is likely because, as our findings related to 
discharge year suggest, practice was already changing before the creation of the 
guidelines. Each additional year from 2015 to 2019 resulted in lower odds of leaving with 
an opioid only and higher odds of leaving with a non-opioid. The guidelines, released in 
2017, did not significantly change this already declining trend. The observed association 
between the post-guideline period and lower odds of being discharged with both an 
opioid and a non-opioid is likely related to the lower odds of receiving an opioid over 
time in this sample (Figure 4.1). As such, the guidelines are likely a reflection of current 
practice, rather than the driver of prescribing changes in this time period. We did not find 
a significant association between the guidelines and lower prescribed dosages. Again, this 
is likely because dosage was already decreasing over time. This considered, the change in 
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dosage is notable, as lack of statistical significance does not imply lack of clinical 
significance. Even though prescribing has been declining for on the national level for 
several years, it remains higher than the late 1990s.3 Consequently, it will be important to 
consider the role guidelines, such as those in Pennsylvania, play in sustained prescribing 
practices over time.  
The observational nature of this study has inherent limitations. First, it was conducted 
at one institution, thus limiting its applicability to other settings and populations. Second, 
the sample consisted of all discharges of 5 days or less. This broad sampling inclusion 
criteria may have contributed to the significant differences between the medication 
discharge groups. Those who left with no pain medications were likely very different 
than those who did. However, the random sampling approach and inclusion of both 
patients who did and did not receive pain medications provides a more accurate snapshot 
of the frequency at which opioid prescribing occurs to the general adolescent population 
seen in acute care settings. The date of Pennsylvania’s safe prescribing guidelines’ public 
release acts only as a proxy and cannot account for how and when the guidelines were 
implemented in practice specific to the study site. Future research will need to compare 
prescribing characteristics across facilities in regions with and without localized 
guidelines, such as a difference-and-difference approach, to best detect the true impact of 
prescribing guidelines.  
While we were able to calculate MME/day dosage, we did not have access to more 
detailed prescribing information such as days supplied. As such, we could not distinguish 
those who left with enough medication for one day from those who had multiple days of 
medication. Similarly, we derived MME/day according to prescription instructions, 
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which does not account for how the medications were used by the patient. Both duration 
of prescriptions and actual use are important considerations for future work on safe 
prescribing. Importantly, our work cannot be used to determine if medications prescribed 
were appropriate for patient indications. We also recognize some non-opioid medications, 
like acetaminophen, have indications other than pain. Despite these limitations, the large 
sample size, spanning several years, adds to the current adolescent opioid prescribing 
literature.  
In conclusion, adolescents in our sample left with fewer opioids, and more non-opioid 
medications over time, even when adjusting for relevant patient and clinical 
characteristics. This decrease began before the implementation of Pennsylvania’s 
prescribing guidelines for pediatric and adolescent populations. Future work should 
continue to evaluate prescribing while incorporating patient outcomes to determine the 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4.2 Multivariable Multinomial Logistic Regression Derived Odds of Discharge 
Medication Groups 
 
Opioid only  
AOR (95% CI) 
Non-opioid only  
AOR (95% CI) 
Both opioid and non-
opioid  
AOR (95% CI) 
Discharge Year 0.79 (0.66-0.94)* 1.34 (1.26-1.46)* 1.06 (0.94-1.19) 
Discharged Post-
guideline 
0.83 (0.73-0.93) 1.07 (1.01-1.14) 0.91 (0.84-0.99) 
   No Reference - - - 
   Yes 0.70 (0.41-1.19) 0.76 (0.59-0.97) 0.59 (0.42-0.84)* 
Age 1.06 (1.01-1.12) 0.97 (0.95- 1.00) 0.97 (0.94-1.01) 
Race    
   White Reference - - - 
   Black 1.31 (0.95-1.81) 0.88 (0.75-1.03) 1.31 (1.04-1.64)* 
   Other/Unknown 0.87 (0.59-1.30) 1.02 (0.85-1.22) 0.92 (0.71-1.18) 
Insurance    
   Private Reference - - - 
   Medicaid/self-pay 0.83 (0.62-1.11) 1.10 (0.95-1.27) 0.85 (0.70-1.04) 
Unit    
   ICU Reference    
   Medical 1.32 (0.88-1.99) 0.86 (0.71-1.04) 3.45 (2.57-4.63)* 
Inpatient Opioid    
   No Reference - - - 
   Yes 31.10 (19.72-49.05)* 1.94 (1.65-2.27)* 43.07 (32.72-56.70)* 
Mental Health 
Diagnosis 
   
   No Reference - - - 
   Yes 0.51 (0.33-0.78)* 0.58 (0.49-0.69)* 0.44 (0.34-0.57)* 
Surgery    
   No Reference - - - 
   Yes 7.73 (5.75-10.38)* 4.53 (3.84-5.36)* 46.92 (37.67-58.42)* 
Average Pain 1.43 (1.35-1.53)* 1.37 (1.33-1.42)* 1.48 (1.42-1.55)* 
Length of Stay, days 0.83 (0.73-0.93)* 1.07 (1.01-1.14) 0.91 (0.84-0.97) 
Reference medication group = discharged with no medication; CI = Confidence interval; AOR = Adjusted 
Odds Ratio; ICU = intensive care unit 




Table 4.3 Dosage in MME/day by Temporal Factor 
Temporal Factor Dosage in MME/day 
(median [IQR] 
P 
Year  <0.01 
2015 45.0 [41.1-45.0]  
2016 45.0 [32.9-45.0]  
2017 45.0 [32.0-45.0]  
2018 45.0 [30.0-45.0]  
2019 45.0 [30.0-45.0]  
Guideline  0.025 
Pre (August 31st, 2017 and earlier) 45.0 [35.1-45.0]  
Post (September 1st, 2017 and later) 45.0 [30.0-45.0]  
MME/day = morphine milligram equivalents; IQR = interquartile range; Kruskal-Wallis test for year, 
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Chapter 5  
Discussion 
Health care providers and policy makers continue to address the impact of opioid 
consumption, notably in the form of professional organizations’ guidelines and 
prescribing policies.1-4 However, it is imperative these efforts be focused on mitigating 
future risk of over prescribing and misuse in patient populations across health care 
settings, especially young patients. Exposures to substances during adolescence can have 
impact across the lifespan.5,6 As such, it is important to understand medication use and 
opioid prescribing to adolescents. Involved at every level of care, nurses are positioned to 
assesses patients’ pain management needs, characterize prescribing, and develop 
evidence-based approaches to promote safe prescribing practices. The overall objectives 
of this dissertation were to examine factors associated with non-medical use of 
prescription drugs in adolescents and to characterize opioid prescribing to adolescents in 
one of the largest pediatric hospital systems in the country. 
Chapter 2 identified a number of factors that can contribute to the non-medical use of 
prescription drugs, including opioids. These factors may be important for clinicians 
working in acute care settings to assess for and consider when prescribing opioids to 
adolescent patients. Chapter 3 characterized opioid prescribing in a sample of adolescents 
discharged with a pain medication from acute care. Chapter 4 built on this work and 
identified how prescribing changed over time in a large sample of adolescents discharged 
from the inpatient setting. By identifying trends in prescribing pain medications to 
adolescents, researchers will be better informed to develop and implement future 
interventions aimed to promote safe prescribing and safe use of opioid medications in this 
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population. This work contributes to existing knowledge of prescribing trends and is one 
of the first to uniquely focus on adolescent patients discharged from the acute care 
settings. 
Major Findings from Chapter 2  
In this literature review, 32 articles were examined to better understand factors 
contributing to the non-medical use of prescription drugs (NMUPD) in adolescents 
between the ages of 10 and 19. Findings were discussed by categories related to 
demographic characteristics, social environment factors, and health factors. Factors such 
as race, gender, income, and rurality were identified as proxies for the larger context in 
which adolescents live. While these factors are relevant in the development of NMUPD, 
few studies revealed how these characteristics interact with each other or how they both 
influence and are influenced by other contextual factors. Social environment factors like 
peers, school, and family were found to influence NMUPD. However, measures of these 
factors varied greatly, which made comparison difficult. Health factors addressed 
behavior, other substance use, mental health, and physical health. Each topic was linked 
to NMUPD and presented important considerations for health care providers caring for 
adolescent patients. The majority of studies presented in this literature review were cross-
sectional, secondary analyses of large national studies. As such, definitions of factors and 
NMUPD varied, complicating the review’s ability to present succinct findings. Findings 
also varied by both factor and drug, suggesting that future work may benefit from 
delineating drug type. Few studies in this review investigated opioids only, more 
commonly using a composite variable of multiple drug classes. This line of research will 
benefit from longitudinal approaches and both population and drug specific lines of 
 
 112 
inquiry. More findings related to opioids will contribute to physicians, advanced practice 
nurses, and other providers’ ability to weigh the benefits and risks of prescribing an 
opioid while promoting appropriate use of the medications.  
Major Findings from Chapter 3 
This retrospective cross-sectional analysis used the electronic health record (EHR) to 
characterize opioid prescribing in adolescents discharged with a pain medication from the 
emergency department (ED), an urgent care center, or a hospital admission of 48 hours or 
less in one hospital system. The sample included 2,180 adolescent visits from January 
2015 to January 2017, of which 35.5% resulted in an opioid prescription at discharge. 
The final multivariable logistic regression included age, race, surgery, insurance, last pain 
score before discharge, and care unit. Every year of age was associated with a 14% 
increase in the likelihood of receiving an opioid prescription. Each 1-point increase in last 
documented pain score was associated with a 15% increase in the odds of being 
prescribed an opioid at discharge. Adolescents who had surgery were nearly twice as 
likely to leave with an opioid compared to adolescents who did not have surgery. 
Individuals with Medicaid coverage or who self-pay were 34% less likely to be 
prescribed an opioid at discharge compared to individuals with private insurance. 
Compared to medical floors, those discharged from the ED and urgent care centers had 
significantly lower odds of being prescribing an opioid, while those discharged from a 
surgical floor had the greatest odds. We did not find significant differences by gender, 
race, or prescriber licensure. While data was extracted regarding, smoking, alcohol, and 
substance use, it was largely missing, and thus not included in our analysis. Given that 
these behaviors are important considerations when prescribing an opioid, future work 
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may benefit from capturing these factors. Our sample was from one hospital system and 
comprised of only patients who were discharged with a pain medication, thus it is not 
generalizable to other populations. Further, we did not examine the dosage prescribed 
upon discharge. Limitations considered, this study was amongst the first to characterize 
opioid prescribing practices among adolescents following short-term hospitalization. 
Efforts to promote safe opioid use in adolescents requires an understanding of the current 
context of prescribing. These findings can be used to inform nursing practice, specifically 
informing how nurses in acute care settings may need to assess various patient factors 
associated with being discharged with an opioid. 
Major Findings from Chapter 4 
This study examined opioid prescribing to adolescents over time at one hospital. As such, 
the purpose of this study was to examine changes in opioid prescribing to adolescents 
upon discharge from acute care over time at one large urban pediatric academic medical 
center. Notably, this chapter examined how opioid prescribing changed following the 
introduction of the Safe Prescribing of Opioids in Pediatric and Adolescent Populations 
guidelines in 2017 within Pennsylvania. The analysis of a random sample of 9,176 
adolescents discharged from acute care between 2015 to 2019 found that 30.4% were 
discharged with an opioid, the majority of which, 88%, also received a non-opioid 
prescription. Further, there was a temporal change in the proportion of adolescent patients 
discharged into four mutually exclusive medication groups year to year: no pain 
medication, non-opioid pain medications only, opioid and non-opioid medications, or 
exclusively opioids. Each subsequent year was associated with 21% decrease in the odds 
of being discharged with only an opioid compared to no medication, and a 34% increase 
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in leaving with a non-opioid medication only. Adjusting for all other relevant covariates, 
being discharged after the release of local guidelines was associated with a 41% decrease 
in the likelihood of being discharged with both an opioid and non-opioid, but no 
significant changes in the odds of being discharged with only an opioid or only a non-
opioid. It is likely that the guidelines were not associated with hypothesized significant 
changes because, as the findings related to year show, practice was already changing 
before guideline implementation. As such, the guidelines likely reflected current practice 
rather than motivated practice change. The association between the guidelines and lower 
odds of being discharged with both an opioid and a non-opioid is likely related to the 
overall decrease in leaving with an opioid observed in the study time period. It will be 
important to continue to evaluate efforts to inform practice over time, beyond the short 
time period included in this study. This study was limited in design and in the use of the 
EHR. The inclusion criteria resulted in a group of adolescents who were discharged with 
no medication, and were likely clinically different than adolescents who did leave with a 
pain medication. As such, there were significant differences between the make-up of each 
medication discharge group. Limitations considered, this work provides a snapshot of 
opioid prescribing to a general adolescent population from one institution.  Methods used 
to conduct this study can be used in future research evaluating nurse-led prescribing 
guideline implementation efforts for adolescent populations. 
 Future Directions 
It is now well known that use of prescription opioids has varied and declined over the 
past decade.3,7,8 However, much of the work examining prescribing trends is descriptive, 
and does not account for patient outcomes. While chapter 4 of this dissertation examined 
 
 115 
average pain over time, more work is needed to better understand the implications of 
declining use of prescribed opioids. While overuse of prescription opioids drove negative 
outcomes in the early 2000s, the negative outcomes we continue to see are largely driven 
by illicit opioids.3 As such, it is important to recognize that decreased prescribing is not a 
positive outcome in itself. Future work should place trends in the context of adolescent 
patient needs and management.  
Use of prescription opioids vary by a number of factors, including the specific patient 
population.2,9,10 Describing trends and promoting guidelines only serve to inform practice 
broadly. While this dissertation focused on wide samples of adolescents, future work will 
benefit from more focused approaches addressing specific patient groups. Such an 
approach would also allow for more nuanced examinations of diagnoses and procedures 
that generally result in an adolescent being discharged with an opioid while identifying 
common and best practices. The National Academies of Science, Engineering, and 
Medicine’s report outlined the need for researchers to monitor the uptake and impact of 
clinical practice guidelines on opioid prescribing for patients, including children and 
adolescents, in acute pain.11 Future research efforts should incorporate key the National 
Academies’ recommendations, such as examining the context of clinical settings on 
prescribing (e.g. acute care) and report findings in morphine milligram equivalents 
(MME).  
This line of work will further benefit from qualitative approaches. Particularly in the 
adolescent population, in which knowledge gaps remain, input from providers will 
contribute to understanding prescribing and shape the incorporation of this research into 
practice. Additionally, the ultimate goal of this work is to contribute to appropriate use of 
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opioid medications. As such, it is necessary to collaborate with adolescents to better 
understand their experiences being discharged with medications and how they are used 
outside the healthcare setting. These efforts can help inform the development of nurse led 
educational interventions that can be implemented when adolescents and their families 
are discharged from acute care settings with opioid medications. 
Conclusion 
In conclusion, this dissertation contributes to an understanding of opioid prescribing to 
adolescents. This work described factors related to the non-medical use of prescription 
drugs in adolescents and characterized opioid prescribing to adolescents at one hospital 
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Sex, n (%)     < 0.001 
   Female 2543 (52.74) 1181 (47.91)  
   Male 2279 (47.26) 1284 (52.09)  
Race, n (%)     < 0.001 
   White 2636 (54.67) 1500 (60.85)  
   Black 1441 (29.88) 595 (24.14)  
   Other 745 (15.45) 370 (15.01)  
Insurance, n (%)     < 0.001 
   Medicaid/self-pay 1827 (37.89) 777 (31.52)  
   Private 2995 (62.11) 1688 (68.49)  
Mental Health Diagnosis, n 
(%) 
1050 (21.78) 231 (9.37) < 0.001 
Surgery, n (%) 382 (7.92) 2221 (90.10) < 0.001 
Inpatient opioid, n (%) 608 (38.80) 2392 (97.04) < 0.001 
Age, mean [SD] 14.55 [2.55] 14.63 [2.41] 0.408 
Length of Stay, days, mean 
[SD] 
2.55 [1.01] 2.67 [1.06] < 0.001 
Average Pain Score, 
median [IQR] 
1.46 [0, 2.39] 3.68 [2.36, 4.86] < 0.001 
Unit type, n (%)     < 0.001 
   Medical 4253 (88.20) 2332 (94.60)  
   ICU 569 (11.80) 133 (5.40)  
Discharge year, n (%)     < 0.001 
   2015 1207 (53.10) 666 (29.30)  
   2016 971 (50.07) 618 (31.87)  
   2017 938 (53.33) 447 (25.41)  
   2018 903 (55.60) 368 (22.66)  




















Sex, n (%)     0.260 
   Female 2543 (52.74) 852 (54.37)  
   Male 2279 (47.26) 715 (45.63)  
Race, n (%)     0.002 
   White 2636 (54.67) 904 (57.59)  
   Black 1441 (29.88) 396 (25.27)  
   Other 745 (15.45) 267 (17.04)  
Insurance, n (%)     0.727 
   Medicaid/self-pay 1827 (37.89) 586 (37.40)  
   Private 2995 (62.11) 981 (62.20)  
Mental Health Diagnosis, n 
(%) 
1050 (21.78) 246 (15.70) < 0.001 
Surgery, n (%) 382 (7.92) 551 (35.16) < 0.001 
Inpatient opioid, n (%) 608 (38.80) 608 (38.80) < 0.001 
Age, mean [SD] 14.55 [2.55] 14.51 [2.51] 0.540 
Length of Stay, days, mean 
[SD] 
2.55 [1.01] 2.71 [1.09] < 0.001 
Average Pain Score, 
median [IQR] 
1.46 [0, 2.39] 3.05 [1.28, 4.53] < 0.001 
Unit type, n (%)     0.032 
   Medical 4253 (88.20) 1350 (86.15)  
   ICU 569 (11.80) 217 (13.85)  
Discharge year, n (%)     < 0.001 
   2015 1207 (53.10) 263 (11.57)  
   2016 971 (50.07) 256 (13.20)  
   2017 938 (53.33) 335 (19.04)  
   2018 903 (55.60) 327 (20.14)  
























Sex, n (%)     0.341 
   Female 2543 (52.74) 161 (50.00)  
   Male 2279 (47.26) 161 (50.00)  
Race, n (%)     0.406 
   White 2636 (54.67) 184 (57.14)  
   Black 1441 (29.88) 97 (30.12)  
   Other 745 (15.45) 41 (12.73)  
Insurance, n (%)     0.075 
   Medicaid/self-pay 1827 (37.89) 106 (32.92)  
   Private 2995 (62.11) 216 (67.08)  
Mental Health Diagnosis, n 
(%) 
1050 (21.78) 30 (9.32) < 0.001 
Surgery, n (%) 382 (7.92) 188 (58.39) < 0.001 
Inpatient opioid, n (%) 608 (38.80) 299 (92.86) < 0.001 
Age, mean [SD] 14.55 [2.55] 15.23 [2.78] < 0.001 
Length of Stay, days, mean 
[SD] 
2.55 [1.01] 2.57 [1.04] 0.837 
Average Pain Score, 
median [IQR] 
1.46 [0, 2.39] 3.94 [2.22, 4.53] < 0.001 
Unit type, n (%)     1.000 
   Medical 4253 (88.20) 284 (88.20)  
   ICU 569 (11.80) 38 (11.80)  
Discharge year, n (%)     < 0.001 
   2015 1207 (53.10) 137 (6.03)  
   2016 971 (50.07) 94 (4.85)  
   2017 938 (53.33) 39 (2.23)  
   2018 903 (55.60) 26 (1.60)  
















Pairwise Comparison of Both Opioid and Non-opioid and Non-Opioid Only Groups 
 






Sex, n (%)     < 0.001 
   Female 1181 (47.91) 852 (54.37)  
   Male 1284 (52.09) 715 (45.63)  
Race, n (%)     0.100 
   White 1500 (60.85) 904 (57.59)  
   Black 595 (24.14) 396 (25.27)  
   Other 370 (15.01) 267 (17.04)  
Insurance, n (%)     < 0.001 
   Medicaid/self-pay 777 (31.52) 586 (37.40)  
   Private 1688 (68.49) 981 (62.20)  
Mental Health Diagnosis, n 
(%) 
231 (9.37) 246 (15.70) < 0.001 
Surgery, n (%) 2221 (90.10) 551 (35.16) < 0.001 
Inpatient opioid, n (%) 2392 (97.04) 608 (38.80) < 0.001 
Age, mean [SD] 14.63 [2.41] 14.51 [2.51] 0.210 
Length of Stay, days, mean 
[SD] 
2.67 [1.06] 2.71 [1.09] 0.458 
Average Pain Score, 
median [IQR] 
3.68 [2.36, 4.86] 3.05 [1.28, 4.53] < 0.001 
Unit type, n (%)     < 0.001 
   Medical 2332 (94.60) 1350 (86.15)  
   ICU 133 (5.40) 217 (13.85)  
Discharge year, n (%)     < 0.001 
   2015 666 (29.30) 263 (11.57)  
   2016 618 (31.87) 256 (13.20)  
   2017 447 (25.41) 335 (19.04)  
   2018 368 (22.66) 327 (20.14)  

















Pairwise Comparison of Both Opioid and Non-Opioid and Opioid Only Groups 
 






Sex, n (%)     0.480 
   Female 1181 (47.91) 161 (50.00)  
   Male 1284 (52.09) 161 (50.00)  
Race, n (%)     0.056 
   White 1500 (60.85) 184 (57.14)  
   Black 595 (24.14) 97 (30.12)  
   Other 370 (15.01) 41 (12.73)  
Insurance, n (%)     0.612 
   Medicaid/self-pay 777 (31.52) 106 (32.92)  
   Private 1688 (68.49) 216 (67.08)  
Mental Health Diagnosis, n 
(%) 
231 (9.37) 30 (9.32) 0.975 
Surgery, n (%) 2221 (90.10) 188 (58.39) < 0.001 
Inpatient opioid, n (%) 2392 (97.04) 299 (92.86) < 0.001 
Age, mean [SD] 14.63 [2.41] 15.23 [2.78] < 0.001 
Length of Stay, days, mean 
[SD] 
2.67 [1.06] 2.57 [1.04] 0.130 
Average Pain Score, 
median [IQR] 
3.68 [2.36, 4.86] 3.94 [2.22, 4.53] 0.101 
Unit type, n (%)     < 0.001 
   Medical 2332 (94.60) 284 (88.20)  
   ICU 133 (5.40) 38 (11.80)  
Discharge year, n (%)     < 0.001 
   2015 666 (29.30) 137 (6.03)  
   2016 618 (31.87) 94 (4.85)  
   2017 447 (25.41) 39 (2.23)  
   2018 368 (22.66) 26 (1.60)  

























Sex, n (%)     0.152 
   Female 852 (54.37) 161 (50.00)  
   Male 715 (45.63) 161 (50.00)  
Race, n (%)     0.065 
   White 904 (57.59) 184 (57.14)  
   Black 396 (25.27) 97 (30.12)  
   Other 267 (17.04) 41 (12.73)  
Insurance, n (%)     0.129 
   Medicaid/self-pay 586 (37.40) 106 (32.92)  
   Private 981 (62.20) 216 (67.08)  
Mental Health Diagnosis, n 
(%) 
246 (15.70) 30 (9.32) 0.003 
Surgery, n (%) 551 (35.16) 188 (58.39) < 0.001 
Inpatient opioid, n (%) 608 (38.80) 299 (92.86) < 0.001 
Age, mean [SD] 14.51 [2.51] 15.23 [2.78] < 0.001 
Length of Stay, days, mean 
[SD] 
2.71 [1.09] 2.57 [1.04] 0.053 
Average Pain Score, 
median [IQR] 
3.05 [1.28, 4.53] 3.94 [2.22, 4.53] < 0.001 
Unit type, n (%)     0.328 
   Medical 1350 (86.15) 284 (88.20)  
   ICU 217 (13.85) 38 (11.80)  
Discharge year, n (%)     < 0.001 
   2015 263 (11.57) 137 (6.03)  
   2016 256 (13.20) 94 (4.85)  
   2017 335 (19.04) 39 (2.23)  
   2018 327 (20.14) 26 (1.60)  


















Single Variable Multinomial Logistic Regression Estimating Odds of Being in 
Discharge Medication Groups 
 
Opioid only  
OR (95% CI) 
Non-opioid only  
OR (95% CI) 
Both opioid and non-
opioid  
OR (95% CI) 
Discharge Year 0.67 (0.61 – 0.74)* 1.21 (1.16 – 1.26)* 0.92 (0.89 – 0.95)* 
Discharged Post-
guideline 
   
   No Reference - - - 
   Yes 0.36 (0.27 – 0.47)* 1.52 (1.36 – 1.70)* 0.75 (0.68 – 0.83)* 
Age 1.12 (1.07 – 1.17)* 0.99 (0.97 – 1.02) 1.01 (0.99 – 1.03) 
Race    
   White Reference - - - 
   Black 0.96 (0.75 – 1.24) 0.80 (0.70 – 0.92)* 0.73 (0.65 – 0.81)* 
   Other/Unknown 0.79 (0.56 – 1.12) 1.05 (0.89 – 1.23) 0.87 (0.76 – 1.00) 
Insurance    
   Private Reference - - - 
   Medicaid/self-pay 0.80 (0.63 – 1.02) 0.98 (0.87 – 1.10) 0.76 (0.68 – 0.84)* 
Unit    
   ICU Reference - - - 
   Medical 1.00 (0.71 – 1.42) 0.83 (0.70 – 0.99)* 2.35 (1.93 – 2.85)* 
Inpatient Opioid    
   No Reference - - - 
   Yes 
93.79 (60.84 – 144.59)* 4.57 (4.00 – 5.23)* 




   
   No Reference - - - 
   Yes 0.37 (0.25 – 0.54)* 0.67 (0.57 – 0.78)* 0.37 (0.32 – 0.43)* 
Surgery    
   No Reference - - - 
   Yes 16.31 (12.76 – 20.34)* 6.30 (5.44 – 7.30)* 105.80 (89.39 – 125.22)* 
Average Pain 1.78 (1.69 – 1.87)* 1.50 (1.46 – 1.55)* 1.70 (1.65 – 1.74)* 
Length of Stay, days 1.01 (0.91 – 1.13) 1.15 (1.09 – 1.21)* 1.11 (1.06 – 1.16)* 
Reference medication group = discharged with no medication; CI = Confidence interval; AOR = Adjusted 
Odds Ratio; ICU = intensive care unit 
* denotes p <0.01 
 
 
 
 
